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Abstract 
Background: Males have a higher prevalence of cardiovascular diseases compared to 
premenopausal women. However, postmenopausal women are at equal risk to men. It has 
therefore been suggested that estrogen is cardioprotective. Although the exact mechanisms of 
the purported cardioprotective effects of estrogen are unknown, estrogen administration has 
been reported to suppress beta-adrenergic receptor up-regulation in ovariectomized female 
rats. As beta-adrenergic activation induces cardiomyocyte apoptosis and necrosis, and hence 
adverse cardiac remodelling and heart failure, I aimed to determine whether the extent of 
beta-adrenergic induced apoptosis and necrosis differs between males and females. 
Methods: 27 male Wistar rats were assigned to one of two groups: ISO M (n=14) receiving a 
beta-adrenergic receptor agonist, isoproterenol (0.02mg/kg) and CON M (n=13) receiving 
vehicle (saline, 0.2ml). 29 female Wistar rats were assigned to one of two groups: ISO F 
(n=15) receiving a beta-adrenergic receptor agonist, isoproterenol (0.02mg/kg) and CON F 
(n=14) receiving vehicle. Isoproterenol and saline were administered by means of daily 
subcutaneous injections for 5 days. On the 5
th
 day, cardiac geometry and function were 
assessed before and after ISO or saline administration using echocardiography. Rats were 
then terminated under anaesthesia within 30 minutes of ISO (or vehicle) administration and 
blood samples collected for the determination of serum estrogen concentration (ELISA). 
Female rats were terminated in proestrus which corresponds to peak estrogen concentrations. 
Cardiac myocyte apoptosis was assessed histologically using the DeadEndTM Colorimetric 
TUNEL system (Promega, Madison, WI, USA). The number of apoptotic cardiomyocyte 
nuclei was expressed as a percentage of the total number of cardiomyocyte nuclei per slide 
(heamotoxylin and eosin stain). Necrosis and fibrosis (pathological score) were assessed by 
assigning a pathological score to sections stained for fibrosis (van Gieson). Groups were 
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compared using two-way (gender and regimen; and including repeated measures for 
echocardiography data) ANOVA followed by the Tukey-Kramer post hoc test.  
Results: As expected estrogen concentrations were higher in female compared to male rats 
(mean±SEM, pg.ml
-1
; ISO M: 7.04±1.41; CON M: 7.14±0.53; ISO F: 23.00±3.47; CON F: 
19.31±3.66; p<0.01). Five days of ISO or saline administration had no effect on cardiac 
function or geometry in either the male or the female rats. Inotropic effects (increased heart 
rate and cardiac function) were observed in response to acute ISO administration in both male 
and female rats. The female rats had slower heart rates (p<0.05) and showed a greater heart 
rate response to acute ISO administration than the male rats (p<0.05). But the acute ISO 
induced increments in cardiac function were similar between genders. Five days of ISO 
administration induced cardiomyocyte apoptosis in male rats but not in female rats 
(mean±SEM, % ; ISO M: 0.086±0.013; CON M: 0.030±0.004; ISO F: 0.053±0.004; CON F: 
0.041±0.007; p<0.05). Furthermore, 5 days of ISO administration induced cardiomyocyte 
necrosis in male rats but not in female rats (mean±SEM, pathological score; ISO M: 
1.21±0.21, CON M: 0.46±0.14, ISO F: 0.50±0.11, CON F: 0.68±0.12, p<0.01). 
Conclusion:  Male rats are more susceptible than female rats to beta-adrenergic induced 
cardiomyocyte apoptosis and necrosis. The protective effects of estrogen against the adverse 
effects of beta-adrenergic activation on the heart, may explain the lower risk of 
cardiovascular disease in premenopausal women compare to men; however, the possible role 
of progesterone cannot be ignored.      
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Preface  
 It is well known that premenopausal women are at a lower risk for cardiovascular 
incidents, such as heart attacks, as compared to men. However, the latter is not true for post-
menopausal women. Indeed, studies have revealed that in post-menopausal women the 
cardiovascular risk profile is equal to that of men. These data allude to the possibility that the 
female hormone estrogen may be cardioprotective (protects the heart). Currently, various 
human and animal studies have been conducted to determine the exact cardioprotective 
mechanisms of estrogen and the overall benefits of estrogen. Results have revealed that 
estrogen protects damaged blood vessels, decreases lipid plaque formation (a negative 
predictor of coronary artery disease), controls blood pressure and prevents bone degeneration; 
all of which are positive outcomes. However, the question still remains how exactly does 
estrogen elicit such cardioprotective effects?    
 In order to evaluate how estrogen is cardioprotective various clinical trials have 
assessed the effects of hormone replacement therapy. Currently, these trials are controversial 
with certain studies revealing beneficial outcomes associated with hormone replacement. 
However, other studies have highlighted the detrimental effects of estrogen use such as 
increased risk of breast cancer, heart attacks and lung complications. Plausible explanations 
for the rather conflicting data obtained from clinical trials include differences in the choice of 
hormone administered, study design, characteristics of women, and the age of women at 
initiation of hormone replacement therapy. In this regard some studies have assessed estrogen 
combined with progesterone; whereas others have assessed estrogen only. The problem with 
administering estrogen and progesterone together, is one cannot conclude which hormone 
(estrogen or progesterone or both) is responsible for the beneficial or detrimental effects of 
hormone replacement therapy. In addition, various clinical trials have used different hormone 
concentrations, the duration of the trials vary widely and the route of administration of 
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hormone replacement therapy is not consistent (either tablets, transdermal patches or 
injections). With regards to the women, some trials have assessed the effects of hormone 
replacement therapy in post-menopausal women; whereas others have assessed peri-
menopausal (just before menopause starts) women. Moreover, in some studies the women 
enrolled had intact uteruses and were healthy; while in other studies the women had a prior 
history of cardiovascular disease. With such variations between studies, it is not surprising 
that the outcomes are inconsistent and hence no decisive conclusions can be drawn.  
In order to overcome the controversies of clinical human trials, animal or laboratory 
based studies have been conducted in an attempt to determine the cardioprotective effects of 
estrogen and the mechanisms thereof. Indeed, great strides have been made with studies 
demonstrating beneficial effects of estrogen especially on the heart, blood pressure and lipid 
concentrations. However, animal studies also have some limitations. Studies using cell 
cultures (in vitro model) are valuable for assessing specific physiological systems in 
isolation; nevertheless the data obtained cannot be extrapolated to a complete organism (for 
example an intact animal). Moreover, in vivo animal studies have chosen aggressive animal 
models of cardiovascular disease which therefore fail to mimic the natural slow progression 
of heart failure. In addition, previous animal studies which have attempted to investigate the 
effects of estrogen, have either removed the ovaries (which produce estrogen), administered 
excessively high levels of exogenous estrogen, or have used estrogen receptor over-
expression models. Thus, currently no study has assessed the cardiovascular effects of the 
naturally cycling endogenous estrogen.  
Hence, my dissertation is aimed at investigating the impact of gender on an 
adrenergic-induced model of cardiovascular disease. The sympathetic nervous system (SNS), 
more specifically beta-adrenergic receptors, plays an important role in the development and 
progression of cardiovascular diseases and is therefore a crucial physiological system to 
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investigate.  The daily administration of a beta-adrenergic agonist (isoproterenol), mimics the 
adrenergic activation which occurs in slowly progressive heart failure in humans. My aim 
was to determine whether gender impacts upon isoproterenol-induced changes in the heart. 
As one of the early changes which occur in the heart is the death of cardiomyocytes, I 
compared the impact of a short period of isoproterenol administration on the geometry and 
function of the heart, as well as cardiomyocyte death by apoptosis and necrosis, in male and 
female rats. 
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Chapter 1 
    Introduction 
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1 Introduction 
A pronounced gender difference exists in the risk of cardiovascular diseases. Males have 
a higher risk than females prior to menopause, after which the gender discrepancy in risk of 
cardiovascular disease is diminished (Hulley et al 1998; Rossouw et al 2002).  Many studies 
have been conducted in an attempt to determine the exact cause of this gender difference. 
These studies have primarily focused on the physiological advantages and disadvantages of 
the exogenous administration of female sex hormones, either estrogen plus progesterone in 
combination or estrogen alone.  
A number of clinical trials have assessed the effects of hormone replacement therapy 
(HRT) in peri- and post-menopausal women. The results are inconsistent in that some trials 
have demonstrated cardioprotective effects (Grady et al 1992); whereas others have shown a 
detrimental effect of HRT on cardiovascular diseases (Hulley et al 1998; Rossouw et al 
2002). In an attempt to clarify the controversies which have arisen from the results of clinical 
trials, various animal- or laboratory-based studies have assessed the effects of estrogen 
administration on the cardiovascular system and the physiological mechanisms thereof. 
In this regard, research has indicated a relationship between estrogen and β-adrenergic 
receptors in the heart; whereby estrogen is thought to down-regulate the β-adrenergic 
receptors (Thawornkaiwong et al 2002). Importantly, the sympathetic nervous system (SNS) 
is known to play a crucial role in cardiovascular diseases. Indeed, increased β-adrenergic 
receptor activation induces myocardial infarction, heart failure and progressive myocardial 
dilatation. Nevertheless, the cardiovascular effects of estrogen in the presence of increased β-
adrenergic receptor activation are currently unknown. As chronic β-adrenergic receptor 
activation is the most important factor that promotes progressive heart failure (Badenhorst et 
al 2003), further research to assess the potential benefits of estrogen is crucial.   
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Although, the most effective way to counteract the effects of SNS activation on the 
cardiovascular system is by the use of β-adrenergic receptor blockers (Metra et al 2000), only 
15% of all patients with heart failure are able to tolerate these agents because they reduce 
myocardial contractility (Metra et al 2000). Hence, it is important to understand the 
mechanisms (pathways downstream from β-adrenergic and estrogen receptors) which may be 
responsible for progressive heart failure or the prevention thereof, as well as which patients 
are most likely to benefit from these agents. 
 
1.1 The controversies regarding the cardiovascular effects of oestrogen 
administration 
1.1.1 Human clinical trials 
Numerous clinical trials have been performed to determine the potential 
cardiovascular benefits of HRT. A summary of the most pertinent human studies is provided 
in Table 1. The results of these clinical trials are inconsistent. Some studies demonstrate 
cardioprotective effects of estrogen, such as lowered  atherosclerotic plaque progression, 
improved lipid profile (Mansen et al 2007), and reduced risk for myocardial infarction 
(Varas-Lorenzo et al 2000) and coronary artery disease (Grady et al 1992). Conversely, other 
studies have shown HRT to have detrimental consequences, such as increased risks of breast 
cancer, coronary heart disease and pulmonary emboli (Hulley et al 1998; Roussow et al 
2002). It is therefore imperative to critically analyse the clinical trials that have been 
performed thus far, to try and understand the reasons underlying the controversies related to 
the effects of estrogen administration. 
The Heart and Estrogen/Progestin Replacement Study (HERS) (Hulley et al 1998), a 
randomised blinded control study, in post-menopausal women younger than 80 years of age, 
who had previously undergone a hysterectomy and who had established coronary heart   
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Table 1: Summary of human trials 
 
Author Patient type HRT combination Duration Outcome Overall 
conclusion 
Arnlov et al 
2006 
Middle aged white men 
with no CVD at baseline 
(mean age 56 years) 
None assessed endogenous 
estradiol levels 
Ten year follow-
up 
 Higher estradiol levels were associated 
with lower risk of CVD events in older 
men. 
 Testosterone and DHEA-S levels did 
not alter risk of CVD events. 
 estradiol =  
CVD risk 
Grady et al 
1992 
Peri- menopausal and post 
menopausal women 
 
Meta- analysis of studies.  
Regimens included:  
1. estrogen only 
2. estrogen and progestin 
Studies ranged 
from  3-10 years 
 Estrogen therapy reduced the risk of 
CHD and hip fracture 
 Long term estrogen use was associated 
with increased risk of endometrial and 
breast cancer 
Estrogen  CHD 
but estrogen  
cancer risk 
Hulley et al 
1998 
(HERS) 
Post- menopausal with 
established coronary 
disease and intact uterus 
mean age 66.7 years (55-80 
years) 
Experimental group: Conjugated 
equine estrogen and progesterone 
(medroxyprogesterone) 
Control group: Placebo 
Span of four 
years with data 
recorded in year 
one and four 
 No difference between groups in 
primary and secondary outcomes 
 Lower low-density lipoprotein levels in 
experimental group 
 Increased CHD events within the first 
year followed by lower CHD events in 
the fourth and fifth years in the 
experimental group  
HRT  CHD after 
4 years 
Manson et al 
2007 
(sub study of 
WHI) 
Early post menopausal 
women with hysterectomy 
aged 50-59 years 
Experimental group: Conjugated 
equine estrogen 
Control group: Placebo 
Follow-up 
period seven 
years 
 Experimental group had 30-40% less 
coronary artery calcium build up 
compared to placebo group 
 Experimental group required less 
procedures to reopen clogged arteries  
HRT   
atherosclerosis  
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Author Patient type HRT combination Duration Outcome Overall 
conclusion 
Miller et al 
2008 
(KEEPS) 
Healthy menopausal 
women aged 42-58 years 
Experimental group: estrogen only 
HRT 
Control: placebo 
Four years  Still awaiting results     - 
Psaty et al 
1994 
Post-menopausal women 
with a history of fatal or 
non-fatal MI aged 68 years 
Group 1: HRT nonusers 
Group 2: estrogen only HRT 
Group 3: estrogen + progestin HRT 
Period of two 
years 
 Risk ratio of MI in estrogen only users 
was 0.69 
 Risk ratio of MI in estrogen and 
progestin users was 0.68 
Estrogen= estrogen 
+ progestin 
Roussouw et 
al 2002 
(WHI) 
Post-menopausal with no 
history of cardiovascular 
disease with intact uterus 
aged 50-79 years 
Experimental group: Conjugated 
equine estrogen and progestin 
(medroxyprogesterone) 
Control group: Placebo 
Follow-up 
period of five 
years 
 Lower low-density lipoprotein levels in 
experimental group 
 Global index of benefit versus risk 
revealed HRT to be harmful (CHD 
events and breast cancer) 
HRT  CHD but 
 LDL cholesterol  
Varas-
Lorenzo et 
al 2000 
Post- menopausal women 
with no history of 
cardiovascular disease 
(aged 50-74 years) 
1. Non- users 
2. HRT users 
 oral  
  Estrogen alone 
  Estrogen + Progestin (conjugated) 
 transdermal  
  Estradiol 
  Estradiol + Progestin (conjugated) 
estradiol implants 
Follow-up from 
six months to 
three years 
 
 Overall HRT users had a reduced risk 
for MI compared to non-users 
HRT   risk of MI 
 
CHD, coronary heart disease; CVD, cardiovascular disease; DHEA-S,dehydroepiandrosterone sulfate; HERS, Heart and Estrogen/Progestin 
Replacement Study; HRT, hormone replacement therapy; KEEPS, Kronos Early Estrogen Prevention Study; LDL, low density lipoprotein; MI, 
myocardial infarction: WHI, Women’s Health Initiative. 
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disease (defined as one or more of the following: myocardial infarction, coronary artery 
bypass graft surgery, percutaneous coronary revascularisation or angiographic evidence of at 
least 50% occlusion of one or more major coronary arteries), assessed the effects of HRT 
(estrogen and progesterone) on coronary heart disease (CHD). The primary outcomes were 
the occurrence of non-fatal myocardial infarction (MI) or CHD deaths (described as fatal MI, 
sudden death within one hour of symptoms, death due to coronary revascularization 
procedures or congestive heart failure) over a period of 5 years. Secondary outcomes were 
coronary revascularization, unstable angina, congestive heart failure, resuscitated cardiac 
arrest, stroke and peripheral arterial disease. The participants were monitored every 4 months 
however results were expressed per year. Overall the results revealed no significant 
differences between the two groups (HRT versus placebo) with respect to primary outcomes. 
The HRT group however, were noted to have decreased low-density lipoprotein (LDL) and 
increased high-density lipoprotein (HDL) cholesterol concentrations compared to the placebo 
group after 1 year and after 5 years. Moreover, the trial revealed that the HRT group had 
increased incidence of CHD within the first year of the study; however in the fourth and fifth 
years of follow-up the HRT group had decreased CHD events compared to the placebo 
group. Although, HRT had no effect on the prevalence of the primary outcomes after 1 year, 
long-term HRT use could offer possible myocardial protection, as noted from the decrease in 
CHD events in the 4th and 5th years of the study. The HERS study failed to assess heart 
failure progression. Indeed, in this trial the results were assessed after a maximum of 5 years, 
which may have been too short a time period to fully determine the potential cardiovascular 
benefits of HRT in preventing heart failure progression (Hulley et al 1998). Moreover, as the 
experimental group where receiving combination HRT (estrogen plus progesterone), the 
potential benefits of estrogen alone could not be assessed.    
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A question which arose from the HERS study is whether HRT would potentially be 
beneficial in healthy post-menopausal women. Thus,  the Women’s Health Initiative (WHI) 
trial evaluated the effects of HRT (estrogen plus progestin) on CHD events in healthy post-
menopausal women aged from 50-79 years, who had an intact uterus but had no history of 
CVD (Rossouw et al 2002).   To determine the health benefits versus risks of HRT a global 
index was determined and compared between the experimental and placebo groups. The 
global index was described as the earliest occurrence of CHD (more specifically acute MI 
requiring overnight hospitalisation, silent MI or CHD death), invasive breast cancer, stroke, 
pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to 
other causes. The trial was stopped prematurely as a significant portion of the participants in 
the experimental group (estrogen plus progestin) presented with breast cancer, CHD, stroke 
and pulmonary emboli. However, some of the results were similar to those of the HERS trial, 
in that the experimental group had lower LDL and increased HDL cholesterol levels. With 
respect to the global index, the experimental group had lower hip fracture rates compared to 
the placebo group; however, the experimental group had higher incidences of non-fatal MI, 
strokes, venous thrombo-embolism and non-fatal events compared to the placebo group. Thus 
the global index demonstrated an overall harmful effect of HRT. The unfavourable outcomes 
of this trial may be related to certain limitations namely: (i) the doses of estrogen and 
progestin may have been too high [indeed the authors suggested that transdermal 
administration could have been more physiologically favourable (Rossouw et al 2002)]; (ii) 
the effects of estrogen alone or progesterone alone could not be determined as HRT was 
administered as a combination. It is plausible that progestin could have masked any beneficial 
effects of estrogen. Hence, similar to the HERS trial; whether estrogen alone was 
cardioprotective could not be assessed in WHI trial. 
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Some of the issues that may have contributed to the conflicting results obtained in the 
HERS and WHI trials (decreased versus increased CHD events respectively), were addressed 
in a population-based case-control study conducted by Varas-Lorenzo et al (2000). The 
participants enrolled in this study were similar to those enrolled in the WHI trial. Participants 
were between 50-74 years of age, had no history of cardiovascular events, and either had an 
intact uterus or their uterus had been surgically removed. The participants were stratified 
according to the type of HRT used, namely: oral estrogen alone; transdermal estrogen alone; 
implants of estradiol alone; estrogen plus progestogen; and non-users. The aim of this study 
was to assess the incidence of MI and to correlate the incidence of MI with the route of 
administration, dose and duration of HRT. The results revealed that the age-adjusted odds 
ratio (OR) for MI in participants taking HRT, irrespective of route of administration, over a 
period of 6 months was 0.72 compared to non-users. Compared to non-users, those 
participants that had used HRT for more than 1 year had an OR of 0.68, and those that had 
used HRT for more than 3 years had an OR of 0.59. In addition the protective effects of long-
term (>1 year) HRT use were better for fatal events than non-fatal events (OR=0.38 and 0.77 
respectively). In addressing some of the limitations of the WHI trial this study showed that 
long-term HRT (>1 year) had lower risk for MI compared to short-term use (6 months). 
These results are in agreement with the HERS trial where long-term (4 and 5 years) 
administration had more favourable cardiovascular results compared to short-term use (1 
year). A possible explanation for the latter is described by the meta analysis of Grady et al 
(1992) that stated that long-term (more than 3 years) estrogen therapy was imperative for 
improving CHD as it is a chronic progressive disease (further explanation is found on page 
11). Regarding the route of administration, transdermal users had an OR of 0.75 and oral 
users an OR of 0.66. It is important to note however, that with respect to the latter results 
transdermal users were only 21% of the users and hence a sample size of 22, compared to the 
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oral estrogen group which had a larger sample size of 63 participants. The dosage of the 
hormones was also assessed and revealed that high doses of HRT had an OR of 0.75, medium 
doses an OR of 0.59, and low doses an OR of 0.96. Hence, medium doses were optimal, 
confirming the concerns raised by the authors of the WHI trial (Rossouw et al 2002), that the 
unfavourable outcomes observed in WHI may be the result of doses of estrogen and progestin 
that were too high. 
In this population-based case-control study, Varas-Lorenzo et al (2000), also 
evaluated the effects of opposed estrogen (estrogen plus progestogen) and unopposed 
estrogen (estrogen alone) HRT regarding the risk of MI. The results revealed that unopposed 
HRT had an OR of 0.52 compared to opposed HRT which had an OR of 0.79 and as stated by 
the authors unopposed therapy had a greater risk reduction (Varas- Lorenzo et al 2000). 
These data showing that unopposed estrogen had a lower risk of MI, is crucial as it addresses 
one of the many limitations of the WHI trial where only opposed estrogen HRT (estrogen 
plus progestin) was used. Thus to summarise, when estrogen HRT was assessed alone, the 
route of administration (transdermal versus oral), the dosage and the duration of use 
influenced the results obtained with respect to risk of MI. Importantly, Varas-Lorenzo et al 
(2000) demonstrated a cardioprotective effect (decreased risk of MI) of long-term, medium-
dose, estrogen alone HRT in healthy post-menopausal women. However, whether the same 
results would be observed in post-menopausal women with CHD remained to be assessed.              
Bearing in mind the favourable effects of HRT on cholesterol levels (HERS and WHI 
trials), and the fact that the presence of atheromatous plaques increases the risk of 
cardiovascular events, a sub-study of the WHI trial determined the effect of conjugated 
equine estrogen HRT on calcified plaque formation in the coronary arteries of healthy, 
younger (aged 50-59 years) post-menopausal women after a follow-up period of 7.4 years 
(Manson et al 2007). The experimental group had significantly lower plaque formation 
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compared to the placebo group. The beneficial effects of HRT observed in this trial were in 
accordance with the lower risk of MI observed with medium-dose estrogen alone (Varas-
Lorenzo et al 2000) and hence add plausibility to the cardioprotective effects of estrogen. 
However, as only younger post-menopausal women were assessed, whether the same 
outcomes would occur in older post-menopausal women is not known. Moreover whether 
conjugated estrogen HRT has an effect on established atheromatous plaques was not 
evaluated in this study as only healthy (no history of CVD) post-menopausal women were 
assessed (Manson et al 2007).  
A question which therefore arises is whether the effects of HRT are dependent on the 
presence or absence of CVD. In this respect Psaty et al (1994), conducted a population-based, 
case-control study in post-menopausal women who had previously experienced either a fatal 
or a non-fatal MI. In this study cases were post-menopausal women who presented with a 
fatal or non-fatal MI, and controls were age-matched to cases. The participants were stratified 
according to HRT use namely: nonusers; estrogen alone; or estrogen plus progestin 
(combined therapy). The aim of this study was to determine whether HRT has 
cardioprotective effects after adjusting for major coronary risk factors and co-morbid 
conditions. The results demonstrated that the risk ratio for an MI was not different between 
the estrogen alone users and combination HRT users (risk ratios of 0.69 and 0.68 
respectively). However it is important to note that the study had a small sample size and was 
a case-control design as opposed to a randomised control study (HERS and WHI trials), two 
factors which limit the statistical power of the study. Moreover, the authors did not calculate 
the relative risk of the non-user group, thus failing to assess whether non-users did in fact 
have a higher risk ratio for an MI as compared to the HRT users (Psaty et al 1994).  
A further study which provides some clarity on the possible factors contributing to the 
contradictory outcomes of HRT clinical trials is a meta-analysis of 32 trials. Grady et al 
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(1992) designed a meta-analysis to assess the benefits and risks of HRT in peri-menopausal 
and post-menopausal women and assessed studies investigating the effects of estrogen 
therapy alone and combination therapy on endometrial cancer, breast cancer, coronary artery 
disease (CAD) and stroke. This meta-analysis revealed that estrogen therapy alone lowered 
the risk for CAD and was beneficial for women who had undergone hysterectomies as well as 
patients with CHD or at high risk of CHD (Grady et al 1992). Grady et al (1992) stated that 
long-term (more than 3 years) estrogen therapy was imperative for improving CHD as it is a 
chronic progressive disease. Indeed, in the HERS trial, the decrease in CHD events was noted 
in the fourth and fifth years of follow-up but not in the first year of follow-up. In accordance 
with these data, Varas-Lorenzo et al (2000) demonstrated that the odds ratios for an MI were 
significantly decreased in participants who had been taking HRT for 3 years as compared to 
only 6 months or 1 year.  
In addition to the duration of HRT, Mendelsohn and Karas (2005) revealed that the 
age at which HRT is started is extremely important.  The “timing hypothesis” as it is known 
states that if HRT is started early, before an atherosclerotic plaque has advanced, HRT can be 
beneficial by reversing endothelial dysfunction. However, if the plaque is advanced, HRT 
may induce inflammatory and haemostatic complications (Mendelsohn and Karas 2005). This 
“timing hypothesis” could be a plausible explanation for the discrepancies between the trials 
discussed above. Indeed, in the trials that have shown beneficial outcomes, the participants 
were younger when HRT was initiated (Manson et al 2007; Varas-Lorenzo et al, 2000) as 
compared to the participants in the trials in which HRT was shown to be detrimental 
(Rossouw et al 2002). Thus the timing of initiation and duration of HRT plays a significant 
role in the effects of HRT on cardiovascular outcomes in patients.   
Another issue with respect to HRT is whether estrogen is gender specific or only 
elicits a cardioprotective effect in females. To investigate the possible impact of gender on 
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cardiovascular effects of estrogen, Arnlov et al (2006) conducted a prospective cohort study 
in men. The effect of endogenous estrogen levels on risk of CVD in men was determined. 
The results revealed that older men (>56 years) with higher estrogen levels had decreased risk 
for CVD events, even after adjustments for cardiovascular risk factors. Unlike testosterone 
levels which decrease with age in men, estrogen concentrations in men remain relatively 
constant. Hence, with age the ratio of estrogen to testosterone concentration would increase 
and estrogen could therefore elicit a beneficial response (Arnlov et al 2006). Plausible 
mechanisms of how estrogen is cardioprotective in men include decreases in blood pressure, 
lipid and glucose levels (Arnlov et al 2006). An important issue which needs to be addressed 
is whether testosterone is harmful to the myocardium. Indeed,  Cavasin et al (2003) revealed 
that castrated male mice and intact male mice  receiving exogenous estrogen post MI had 
increased ejection fraction and reduced left ventricular dimensions as compared to sham 
castrated mice;  thus suggesting that estrogen  administration post MI prevents deterioration 
of cardiac functioning and remodelling and conversely testosterone exacerbates myocardial 
dysfunction and remodelling (Cavasin et al 2003). Plausible mechanisms of how testosterone 
is harmful to the myocardium include an impaired coronary artery relaxation (Ceballos et al 
1999), androgen receptor induced increases in myocyte hypertrophy (Marsh et al 1998) and 
enhanced myocyte apoptosis (Zaugg et al 2001). Although it has been suggested that 
testosterone may be detrimental to the myocardium (Cavasin et al 2003), this data is 
controversial. Webb et al (2008) demonstrated in a randomised, placebo controlled, crossover 
design that men aged 40-75 years with known CHD and low levels of testosterone had 
increased myocardial perfusion through unobstructed coronary arteries after administration of 
testosterone for a period of 8 weeks. However, testosterone treatment had no effect on overall 
myocardial perfusion, global endothelial function, quality of life and angina symptoms 
(Webb et al 2008).  The authors stated that an increased myocardial perfusion could impact 
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on arterial stiffness which is a predictor of cardiovascular outcomes. However, oral 
testosterone had no effect on endothelial function or angina symptoms thus revealing that the 
benefits of testosterone are limiting. Indeed, further research is crucial in understanding the 
mechanisms and effects of testosterone on the cardiovascular system.    
Lastly, it is possible that differences in study design and characteristics of the 
participants may contribute to the controversies about the potential benefits of HRT (see 
Table 1).  In order to resolve the controversies between observational / case-control (Psaty et 
al 1994; Varas-Lorenzo et al 2000) and randomised control studies (Hulley et al 1998; 
Rossouw et al 2002; Manson et al 2007), the Kronos Early Estrogen Prevention Study 
(KEEPS) is a randomised, double-blind placebo control trial which is currently enrolling 
healthy (no CHD risk factors) women participants  aged 42-58 years old, between 6-36 
months from their final menses, and with intact uteruses (Miller et al  2008). The aim of 
KEEPS is to address the controversies between the WHI trial and observational studies by 
starting HRT at a young age and at the start of menopause and evaluating whether early 
intervention of HRT will lower the risk of CHD events and the formation of atherosclerotic 
plaques (Miller et al  2008). The trial will be completed in 2010 and will hopefully 
demonstrate whether early intervention is the key to estrogen being cardioprotective. 
However, even if the KEEPS trial does reveal that estrogen HRT is beneficial, the need for 
further experimental research is critical in order to determine the mechanisms of the 
cardioprotective effects of estrogen. 
Thus in conclusion it can be seen that although numerous clinical trials have been 
performed the evidence from the different trials is controversial (Table 1). To summarise, 
many of the trials are heterogeneous and difficult to repeat as the participants’ characteristics 
differ (i.e.  presence or absence of existing CVD). In addition many of the trials use estrogen 
and progestin together and thus the effect of either hormone alone cannot be determined. The 
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regime and dosage of HRT is also diverse amongst trials and therefore results are not 
comparable between studies. Furthermore, in those studies including participants with CHD, 
the CVD is heterogeneous in aetiology. The latter is important to consider as the 
consequences of an MI are different from those of a stroke, and hence the potential impact of 
estrogen on these CVD may differ. Thus to overcome these confounding factors, it is crucial 
to conduct well controlled studies. In this regard, laboratory bred animals and animal models 
of disease are more homogenous than their human counterparts. Moreover in animal studies, 
as invasive and terminal experiments are possible, one can assess specific physiological 
mechanisms that could possibly explain the potential cardioprotective effects of estrogen. 
 
1.2 Animal research studies 
As previously discussed, the outcomes of studies conducted in humans are 
controversial possibly because of associated confounding factors that are difficult to avoid. 
However, animal models allow for the control of many of these confounding factors. 
Moreover, in animal studies, but not in human studies, specific physiological systems can be 
isolated and manipulated, hence allowing for the assessment of the possible mechanisms of 
the potential cardioprotective effects of estrogen. Therefore it is crucial that animal studies be 
conducted to try and elucidate whether estrogen is cardioprotective and the exact mechanisms 
thereof. In this regard, numerous animal studies have investigated the role of estrogen on 
various physiological systems. These studies, which are summarised in Table 2, will be 
discussed in the subsequent sections. Although many of these animal studies have 
demonstrated a beneficial effect of estrogen on CVS risk, these studies present with 
numerous limitations pertaining to the model of CVS disease assessed or the methods used to 
manipulate estrogen concentrations. Hence, the animal studies will be discussed with regards 
to the impact of the different models used and the methods of estrogen manipulation.  
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Table 2: Summary of animal studies 
Author Animal Model Manipulation of 
estrogen 
In vivo/  
Ex vivo 
Outcome Overall conclusion 
Booth et al 
(2003) 
Left anterior 
descending 
coronary artery 
ligation(LAD) 
Ovariectomised female rabbits 
receiving endogenous 17β 
estradiol 
In vivo  17β estradiol treated rabbits had smaller 
infarct sizes compared to controls 
17β estradiol  infarct 
size 
Booth et al 
(2005) 
Left anterior 
descending 
coronary artery 
ligation(LAD) 
Ovariectomised female rabbits 
receiving endogenous 17β 
estradiol, ER selective agonists 
(α and β). 
In vivo  Rabbits treated with ER-α agonists had 
smaller infarct sizes compared to ER-β 
and 17β estradiol treated rabbits  
ER-α possibly mediates 
the cardioprotective 
effects of estrogen 
Dubey et al 
(1998) 
Isolated cardiac 
fibroblasts 
17 β-estradiol, progesterone 
and other estrogen metabolites 
administered to cardiac 
fibroblasts 
Ex vivo  17 β-estradiol and progesterone inhibited 
cardiac fibroblast growth an effect not 
noted with the other metabolites  
17β estradiol+ 
progesterone   
cardiac fibroblast growth 
Gao et al 
(2003) 
Over-expression of 
β-adrenergic 
receptors 
None  In vivo  Lower survival rates in transgenic mice 
compared to controls 
 Male transgenic mice had worse 
cardiomyopathy phenotypes compared to 
female transgenic mice 
  survival in female 
transgenic mice  vs. male 
mice 
 
Kim et al 
(2006) 
Hypoxic re-
oxygenation (H/R) 
17β estradiol administration to 
cardiomyocyte cultures 
Ex vivo  Isolated cardiomyocytes receiving 17β 
estradiol had decreased apoptosis 
compared to control cardiomyocytes 
17β estradiol  
 cardiomyocyte 
apoptosis 
Osadchii et 
al (2007) 
Short term β-
adrenergic agonist 
administration 
(isoproterenol) 
None In vivo  Myocardial fibrosis and apoptosis ISO   apoptosis/ 
fibrosis 
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Author Animal Model Manipulation of 
estrogen 
In vivo/  
Ex vivo 
Outcome Overall conclusion 
Pelzer et al 
(2005) 
            - Ovariectomised female mice 
receiving exogenous 17β 
estradiol 
In vivo  Knockout mice receiving 17 β-estradiol 
had higher mortality rates, body weight, 
fluid retention and biomarkers of heart 
failure compared to controls. 
Estrogen receptor β is 
important in heart failure 
progression 
Ueyama et al 
2007) 
              - Ovariectomised female mice 
receiving exogenous 17β 
estradiol 
In vivo  17β estradiol treated rats had lower heart 
rates, blood pressure compared to 
controls 
 Increased cardioprotective markers in 
rats receiving 17β estradiol 
17β estradiol  heart 
rate/blood pressure 
17β estradiol  
cardioprotective markers 
Van Eickels 
et al (2001) 
Transverse aortic 
constriction (TAC) 
Ovariectomised female mice 
receiving exogenous 17β 
estradiol 
In vivo  Mice receiving 17β estradiol had less 
myocardial hypertrophy compared to 
controls 
17β estradiol  
 myocardial 
hypertrophy 
Van Eickels 
et al (2003) 
LAD (coronary 
artery ligation) 
Ovariectomised female mice 
receiving exogenous 17β 
estradiol 
In vivo  17β estradiol treated mice had smaller 
infarct sizes and cardiomyocyte 
apoptosis and with lower mortality rates 
and myocardial remodelling compared to 
controls  
17β estradiol 
 infarct size/ apoptosis 
Veliotes et al 
(2005) 
Long term β-
adrenergic agonist 
administration 
(isoproterenol) 
None  In vivo  Chronic isoproterenol administration 
induced cardiac dilation and heart failure. 
 Cardiac dilation was prevented with an 
aldosterone receptor antagonist 
(spironolactone)  
Chronic ISOheart 
failureprevented by 
spironolactone 
 
 
 
H/R, hypoxic re-oxygenation; IMO, immobilisation stress model; ISO, isoproterenol; LAD, left anterior descending; SHR, spontaneous 
hypertensive rat; TAC, transverse aortic constriction. 
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1.2.1 Ex vivo models of CVS diseases and manipulation of estrogen in ex vivo 
models 
Cell cultures are often used to elucidate the specific physiological mechanisms of the 
effects of various substances. However, with regards to investigating the mechanisms of the 
effects of estrogen, only a few studies have been performed.   Kim et al (2006), in a study of 
isolated cultured rat cardiomyocytes, revealed that prolonged hypoxic reoxygenation induced 
cardiomyocyte apoptosis (cell death), which was attenuated by 17β estradiol. Hypoxic 
reoxygenation injury generates mitochondrial reactive oxygen species (ROS) which are 
potent stimulators of apoptosis. The latter is important as apoptosis has been shown to occur 
in patients with MI or end-stage heart failure (Guerra et al 1999). Although this study 
demonstrated the possible cardioprotective effects of estrogen, the hypoxic reoxygentation 
model is a very aggressive model for producing cell death. Indeed the percentage apoptosis 
was 3-4% as compared to percentages of 0.25% in males and 0.085% in females as reported 
in patients with MI or end-stage heart failure (Guerra et al 1999). Moreover, the amount of 
apoptosis may have been falsely elevated as a result of the absence of other physiological 
systems such as the influence of nitric oxide on the vasculature (Dubey et al 1998) or the role 
of the renin angiotensin aldosterone system (RAAS) on the myocardium and vasculature 
(Cohn and Colucci 2006) which would normally be present in an in vivo model. In this 
regard, one of the limitations of ex vivo studies is that cells are assessed in an isolated system 
which fails to address all of the natural physiological processes that maintain homeostasis. 
Nevertheless, ex vivo studies have provided some interesting mechanistic information. 
In addition to estrogen’s protective effects against hypoxic reoxygenation induced 
cardiomyocyte apoptosis, the growth of cultured cardiac fibroblasts is inhibited by 17β-
estradiol, its metabolites and progesterone in both genders (Dubey et al 1998). As increased 
cardiac fibroblast growth occurs in patients with hypertension and in patients with MI (Dubey 
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et al 1997), these effects of estrogen and progesterone, as demonstrated in cultured cardiac 
fibroblasts, are of clinical relevance. However, whether these effects were due to estrogen 
alone, progesterone alone or the combination of estrogen plus progesterone could not be 
identified. In addition, estrogen has been shown to inhibit the growth of vascular smooth 
muscle (VSM) cells (Nishigaki et al 1995). Hence, estrogen could possibly attenuate 
myocardial and vascular remodelling by decreasing cardiac fibroblast (Dubey et al 1998) and 
VSM growth (Nishigaki et al 1995) respectively.  
Although the maintenance of cell cultures in an isolated system is certainly beneficial 
in terms of identifying mechanisms independent of possible confounding factors; such 
systems fail to address the impact of a substance (e.g. estrogen) in the presence of other 
factors involved in normal physiological processes. Hence, whether the results observed in 
cell culture systems can be extrapolated to in vivo models is questionable. The benefits of 
estrogen observed ex vivo may not occur in vivo due to for example the presence of other 
possible opposing hormones. Hence to determine whether estrogen has protective effects on 
the CVS, in vivo studies need to be performed.  
 
1.2.2 In vivo animal models of cardiovascular diseases and manipulation of 
estrogen in in vivo models 
1.2.2.1 In vivo animal models of cardiovascular disease 
In order to induce a cardiovascular insult in animals various methods have been 
employed. Most of these methods may be too aggressive hence resulting in rapid progression 
to heart failure, which does not truly represent the fairly slow progression of CVS disease and 
heart failure in humans. For example, animal models of MI have been induced by acute 
ligation of the left anterior descending (LAD) coronary artery (Booth et al 2003); whereas in 
humans MI is most frequently the consequence of progressive atherosclerosis.  Alternatively 
transverse aortic constriction (TAC) has been used to induce pressure overload (Van Eickels 
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et al 2001); which fails to resemble the slow development of essential hypertension in 
humans. Nevertheless, in both of these models estrogen has been shown to be protective. In 
their study to assess the effects of 17β-estradiol on MI size in ovariectomised female rabbits, 
Booth  et al (2003) observed smaller MI and normal sarcomere structures in the 17β-estradiol  
treated ovariectomised rabbits as compared to vehicle treated ovariectomised rabbits (all 
female rabbits in this study were ovarectomised and received either 1)17β estradiol; 
2)vehicle; 3)17α estradiol; 4)17β estradiol receptor antagonist + 17β-estradiol; or 5) 17β 
estradiol receptor antagonist + vehicle ). In addition, ovariectomised rabbits treated with a 
17β-estradiol receptor antagonist plus17β-estradiol had similar MI size as vehicle treated 
ovariectomised rabbits. Similarly, Van Eickels et al (2001) identified that pressure overload 
(TAC) – induced myocardial hypertrophy in ovariectomised female mice, was attenuated by 
both four and eight weeks of 17β-estradiol administration (female mice in all groups were 
ovarectomised and received either: 1)TAC + placebo; 2) TAC + 17β estradiol; 3) sham-no 
TAC + placebo; or 4) sham-no TAC +17β estradiol). As myocardial hypertrophy is a positive 
predictor of cardiac mortality (van Eickels et al 2001), these beneficial effects of estrogen are 
important. Although, the results of these studies highlight the cardioprotective effects of 
estrogen in vivo; they fail to identify the mechanisms of these effects. 
As discussed above, both Van Eickels et al (2001) and Booth et al (2003) used 
aggressive methods to induce myocardial damage (i.e. TAC and LAD coronary artery 
ligation). However, heart failure is normally a slow progressive disease; hence experimental 
models that acutely occlude the aorta or coronary blood vessels and subsequently induce 
myocardial hypertrophy or ischemia such as TAC and LAD coronary artery ligation models 
do not mimic the natural progression of heart failure. Hence alternative models which have a 
slower progression are preferable.  
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In this regard, an alternative to the surgical induction of CVS disease (i.e. TAC or 
LAD coronary artery ligation), is the use of overexpression of the adrenergic receptors. It is 
well established that heart failure is accompanied by an increase in circulating noradrenaline 
which consequently increases the SNS and induces β-adrenergic receptor up-regulation 
(Communal et al 1998). Hence, Gao et al (2003) investigated the effects of β2-adrenergic 
receptor overexpression in male and female mice using a transgenic mouse model. Survival 
rates were lower in the transgenic mice compared to the controls, and moreover male 
transgenic mice had lower survival rates compared to female transgenic mice. The study also 
revealed that transgenic male mice developed LV hypertrophy and LV dilation as well as 
increased myocyte fibrosis, collagen and apoptosis, an effect not demonstrated in the female 
transgenic mice. Although this model of β2-adrenergic receptor overexpression highlights the 
deleterious effects of β2-adrenergic receptor overstimulation, it is unlikely to represent natural 
physiology as the animals are genetically manipulated. Moreover, β2-adrenergic receptor 
overexpression does not allow for the natural progression of heart failure as only one of the 
physiological mechanisms that play a role in influencing heart failure progression is targeted.   
A more physiological animal model which mimics the increased concentrations of 
noradrenaline observed in heart failure is the daily administration of isoproterenol (ISO), a β-
adrenergic agonist. Isoproterenol is an informative drug to use in experimental animal models 
of CVS disease, as detrimental cardiovascular effects are produced with both short-term (5-7 
days) and long-term (5 to 7 months) administration. Short-term administration induces 
myocardial fibrosis and apoptosis (cell death) (Osadchii et al 2007). As apoptosis and fibrosis 
are early indications of heart failure, they are important features to investigate. In this regard, 
future research which leads to early detection and prevention of mechanisms which induce 
heart failure is imperative.  
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Chronic or long-term isoproterenol administration induces cardiac dilatation and heart 
failure (Veliotes et al 2005). As mentioned previously the benefit of using isoproterenol is it 
physiologically mimics the slow progression of heart failure and is not an aggressive model 
unlike other methods namely TAC and LAD coronary artery ligation. However, the 
isoproterenol dosage is also important as extremely high doses induce myocardial 
arrhythmias, premature death and do not mimic natural cardiac compensatory mechanisms 
(Cao et al 2000). Therefore, when using isoproterenol to produce an animal model of CVS 
disease, the dosage should be carefully chosen. Indeed, it is preferable to use a low dose as 
established by Woodiwiss et al (2001) and Veliotes et al (2005). In the latter studies ISO was 
administered at a low dose of 0.02-0.04mg/kg for a period of 4.5 or 7 months. The results 
revealed an increase in LV cavity volumes and reduced pump function. Moreover, long-term 
low-dose ISO administration decreased LV relative wall thickness and increased myocardial 
collagen concentrations (more specifically total, non-crosslinked, type I and type III collagen) 
(Veliotes et al 2005; Woodiwiss et al 2001); characteristics which are observed in patients 
with cardiac dilation and heart failure (Schwartzkopff et al  2002).  Thus, when using ISO 
administration to produce an animal model of slowly progressive CVS disease (as opposed to 
acute MI), long-term low-dose ISO administration is preferable. Nevertheless, to date no 
studies have assessed the role of estrogen in the CVS effects associated with low-dose ISO 
administration. 
In summary, although progress has been made in determining the potential 
cardioprotective effects of estrogen; the results of the current animal studies (either ex vivo or 
in vivo) are not transferable to human CVS diseases. It is therefore imperative to assess the 
effects of estrogen on the cardiovascular system in an animal model of CVS disease that 
closely resembles human CVS disease. In addition, the potential role of estrogen in 
22 
 
 
 
modifying the specific mechanisms that influence heart failure progression such as 
cardiomyocyte apoptosis and necrosis needs to be elucidated.    
 
1.2.2.2 Manipulation of estrogen in in vivo models 
In order to determine the potential cardioprotective effects of estrogen, animal studies 
have focussed on different methods of manipulating estrogen concentrations. Models include 
estrogen receptor knockouts; ovariectomised females receiving exogenous estrogen; and 
intact animals in which the effects of endogenous estrogen is assessed. Although most of the 
studies have used the approach of ovariectomy with exogenous estrogen administration, as 
will be discussed, the disadvantages of this approach is the inhibition of the normal cyclical 
fluctuations in estrogen concentrations. Indeed, some studies have suggested that the 
contradictory detrimental effects of estrogen are related to constant high doses as opposed to 
concentrations which range from high to low at different periods of a normal menstrual cycle 
(Marcondes et al 2002). Nevertheless, cardioprotective effects of estrogen have been 
demonstrated in studies assessing the effects of exogenous estrogen administration in the 
presence of ovariectomy.      
The effects of exogenous estrogen administration to ovariectomised animals include 
decreases in blood pressure and heart rate in rats with increases in circulating adrenaline and 
noradrenaline (Ueyama et al 2007); decreases in cardiomyocyte apoptosis, infarct size, 
ventricular remodelling and mortality rates in mice with LAD coronary artery ligation (van 
Eickels et al 2003) and decreased myocardial hypertrophy in mice with TAC (van Eickels et 
al 2001). Furthermore, in a study using a combination of estrogen receptor knockout, 
ovariectomy and exogenous estrogen administration; increases in mortality, body weight, 
fluid retention and biochemical markers of heart failure were observed in comparison to wild-
type mice (Pelzer et al 2005). However, this study did not demonstrate whether the effects 
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observed were as a result of estrogen receptor knockout or secondary to other physiological 
effects such as renal fluid retention or increases in blood pressure.  
Although beneficial CVS effects of estrogen were demonstrated in these studies, it 
cannot automatically be assumed that similar results would be observed in the presence of 
naturally cycling endogenous estrogen. In this regard, the concentrations of exogenous 
estrogen administered far exceeded the normal physiological range. Indeed, Jang et al (2004) 
revealed that the mean value for normal physiological concentrations of endogenous estrogen 
was 8.4pg.ml
-1
 in female rats and could have possibly been higher as the levels of 
endogenous estrogen fluctuate throughout the rat estrus cycle. To explain further, the female 
rat estrus cycle lasts approximately four to five days and consists of various stages. The four 
stages are proestrus, estrus, metestrus and diestrus. Estrogen levels start increasing in 
metestrus, peak during proestrus and return to baseline in estrus.  Conversely, van Eickels et 
al (2003) demonstrated that ovariectomized female mice receiving exogenous 17β-estradiol 
had  excessively high concentrations of 81pg.ml
-1
  which the authors described as being 
within the physiological range a contrast from levels described by Jang et al (2004) . 
Administering exogenous estrogen is problematic as it is always at a constant concentration 
and does not fluctuate like the normal female menstrual (rodent estrous) cycle. Hence, 
although the animal models discussed in this section have determined the plausible CVS 
benefits of estrogen; they however fail to provide an understanding of the role of naturally 
cycling endogenous estrogen in cardioprotection. Thus it is important to specifically address 
the influence of endogenous estrogen on the myocardium in an animal model. 
 
1.3 The relationship between estrogen receptors and the myocardium 
Having established from human and animal studies that estrogen appears to be 
cardioprotective (at least at constant high doses), it is important to discuss the evidence which 
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supports a direct mechanistic effect of estrogen on the heart. Estrogen is a complex hormone 
which activates different receptors and functions to protect the body in varying organs and 
even in both genders. The identified beneficial effects of estrogen, as well as the different 
estrogen receptors, will therefore be discussed in the context of function, location and 
cardioprotective mechanisms.  
1.3.1 Estrogen receptors 
There are two estrogen receptors, namely α and β. Both receptors bind estrogen with 
the same affinity, are expressed in the heart and vasculature, and have various functions 
(Mendelsohn and Karas 1999). Studies have been conducted to assess the function and 
possible cardioprotective mechanisms of the two estrogen receptors (Figure 1). Certain 
studies favour estrogen α-receptors while other studies emphasize estrogen β-receptors as the 
cardioprotective receptors. The two receptors are discussed below in the context of research 
that has been conducted to date. 
1.3.1.1  Estrogen α-receptors 
The main effects of estrogen α-receptors (ER-α) are on the vasculature. The functions 
mediated by ER-α are the protection of damaged blood vessels by enhancing re-
endothelialization, decreasing atherosclerotic plaque formation and inhibiting smooth muscle 
cell proliferation and matrix deposition (Mendelsohn and Karas 2005). In addition, ER-α 
interact with cytoplasmic proteins, are important in cardiomyocyte structure and stability, and 
play a role in cell-cell interactions (Mahoodzadeh et al 2006). ER-α are reported to be up-
regulated during aortic stenosis and dilated cardiomyopathy (Mahoodzadeh et al 2006). 
Interestingly, Mahoodzadeh S et al (2006) revealed that dilated cardiomyopathy in both 
genders invokes mRNA up-regulation of ER-α. In addition, alterations in the localisation of 
these receptors occur, such that there is a loss of ER-α from the intercalated discs and a co-
localization with β-catenin. It has therefore been postulated that the up-regulation of ER-α  
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Figure 1: Beneficial effects mediated by estrogen receptors (α and β) on cardiomyocytes  
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may be a possible cardioprotective mechanism in response to dilated cardiomyopathy and 
aortic stenosis. Furthermore, during heart failure, the stability of the intercalated discs is 
weakened, and therefore ER-α are up-regulated and their localisation is altered to cope with 
the extra load exerted on the heart (Mahoodzadeh et al 2006). 
The effects of ER-α on post-ischaemic myocardial function, inflammatory signals and 
apoptotic signalling have also been evaluated (Wang et al 2006). In a study comparing ER-α 
knockout mice of either gender to wild type mice, the male wild type mice as well as the ER-
α knockout mice of either gender had myocardial contractile dysfunction; whereas the female 
wild type mice had no myocardial functional impairment. It is important to note that the 
female wild type (who had normal cycling endogenous estrogen), had lower levels of the pro-
apoptotic protein, JNK and elevated levels of extracellular signal-regulated protein kinase 
(ERK), which assists in myocardial functional recovery after ischaemic reperfusion injury.    
In this regard, Booth et al (2005) demonstrated the cardioprotective effects of ER-α in 
an ischaemic-reperfusion model (LAD coronary artery ligation for 30 minutes followed by 
reperfusion). Intact rabbits as well as ovariectomised female rabbits were used in the study. 
Three groups of rabbits were used: group 1 consisted of intact rabbits receiving ER-α agonist, 
estrogen β-receptor (ER-β) agonist, 17 β-estradiol, and vehicle; group 2 consisted of intact 
rabbits receiving ER antagonist+ ER-α agonist, ER antagonist + 17β-estradiol, and ER 
antagonist + vehicle; group 3 consisted of ovariectomized female rabbits and received the 
same regimen as group 1. The results demonstrated that infarct sizes were smaller in intact 
rabbits treated with ER- α agonist and 17β-estradiol but not ER-β agonist. In addition, ER- α 
agonist and 17β-estradiol treated rabbits had similar infarct sizes when treated with the ER 
antagonist, thus highlighting the cardioprotective effects of estrogen and more specifically 
ER-α. The results also revealed that ER-α agonist and 17β-estradiol treated rabbits had 
decreased levels of  C-reactive Protein (CRP) and cardiac-specific Troponin I (cTn1); 
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markers of myocardial damage, an effect not observed in the ER- β agonist treated rabbits. 
These results suggest that the cardioprotective effects of estrogen are mediated by estrogen α-
receptors but not by estrogen β-receptors. Interestingly, ovariectomized female rabbits treated 
with vehicle had larger infarct sizes as compared to intact female rabbits also receiving 
vehicle after ischemic-reperfusion.  The latter emphasises the cardioprotective effects of 
endogenous estrogen.  
A further study confirmed that the cardioprotective effects of estrogen are mediated 
by ER- α (Jeanes et al 2008). In ovariectomised rats an ER-α agonist significantly reduced 
infarct size (in an ischaemic-reperfusion model induced by LAD coronary artery ligation 
followed by reperfusion) and oxidative stress. In comparison an ER-β antagonist produced no 
effect on the ischaemia-induced myocardial injury. The lack of effect of the ER-β antagonist 
(Jeanes et al 2008) in combination with data showing no effect of ER-β agonist on infarct 
size (Booth et al  2005), suggests that ER-β play no role in myocardial ischaemia reperfusion 
injury. However, there is still a possibility that ER-β may be cardioprotective in other models 
of CVS diseases. 
1.3.1.2  Estrogen β-receptors 
Estrogen β-receptors (ER-β) have been shown to play a role in vasodilatation and the 
control of blood pressure in both genders (Mendelsohn and Karas 2005). In addition, the role 
of ER-β in the development of chronic heart failure after MI (LAD coronary artery ligation) 
has been demonstrated in ovariectomised ER-β knockout mice. Eight weeks after the MI, 
mortality rates were higher in the ovariectomised ER-β knockout mice compared to wild-type 
mice; however, no differences in infarct size, cardiac geometry or function (hemodynamic 
and echocardiographic results) were noted between the groups. The higher mortality rates in 
the ovariectomised ER-β knockout mice were associated with increases in body weight, 
pleural effusions, ascites, atrial naturetic peptide levels and phospholamban expression; all of 
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which are markers of heart failure. Hence, although ER-β have no effect on infarct size either 
after MI (Pelzer et al 2005) or in an ischaemic-reperfusion model (Booth et al 2005), ER-β 
demonstrates cardioprotective effects with regards to the development of heart failure. In 
addition, ER-β, but not ER-α, prevent increases in pressure-overload (via TAC) induced 
hypertrophy (Skavdahl et al 2004). Interestingly, the increase in pressure-overload induced 
hypertrophy as a consequence of ER-β knockout was noted in female but not in male mice 
(Skavdahl et al 2004). In addition, male mice had significantly increased pressure-overload 
induced hypertrophy compared to female mice, hence highlighting the underlying 
cardioprotective effects of endogenous estrogen mediated by the ER-β.  
Additional cardiovascular effects noted to be mediated by ER-β include decreases in 
lipoprotein lipase expression (and hence fatty acid metabolism) (Skavdahl et al 2004). 
Moreover, ER-β knockout mice were shown to have prolonged ventricular repolarisation, 
decreased ventricular spontaneity and decreased expression of the voltage-gated potassium 
channels (Korte et al 2005). These effects mediated by ER-β may explain the decreased 
incidence of fatal ventricular tachyarrhythmias in women compared to men (Coa et al 2000).    
In summary, both estrogen receptors play a role in cardioprotection. However these roles 
differ in that the ER-α maintain myocardial contractility, inhibit apoptotic signalling, 
decrease oxidative stress and reduce myocardial infarct size (Pelzer et al 2005; Booth et al 
2005; Jeanes et al 2008; Mahoodzadeh et al 2006); whereas ER-β decrease mortality in 
chronic heart failure, pressure overload hypertrophy, lipoprotein lipase and tachyarrythmias 
(Skavdahl et al 2004; Korte et al 2005). Neither receptor has been established as being more 
important with regards to cardioprotection; however the interaction of these receptors with 
other physiological systems such as the SNS may differ.  
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1.3.2 β-adrenergic receptors and estrogen   
Having established that the most appropriate animal model of slowly progressive 
CVS disease is low-dose ISO administration, it is important to discuss the evidence which 
supports a possible interaction between estrogen and β-adrenergic receptors.   Several studies 
have examined the relationship between the sympathetic nervous system (SNS), its receptors 
and estrogen. The two receptors of the SNS which mediate cardiovascular effects are the α1 
and β1 receptors. In brief the primary cardiovascular effects mediated by α1-receptors are 
vasoconstriction of peripheral blood vessels and hence increases in blood pressure and by β1-
receptors are enhanced myocardial contractility, lusitrophy (relaxation), dromotrophy 
(conduction) and heart rate (Dorn 2002).  
With respect to β1-adrenergic receptors, a relationship with estrogen has been 
demonstrated. Indeed, in ovariectomised mice, a significant up-regulation of β1-adrenergic 
receptors was noted after 10 weeks (Thawornkaiwong et al 2003). In addition, ovariectomy 
induced an increase in calcium responsiveness of cardiac myofilaments.  In this regard, 
bearing in mind that β1-adrenergic receptors increase calcium responsiveness of the 
myocardium (Saito et al 2000) and that long-term β1-adrenergic receptor stimulation is 
detrimental to the myocardium (Communal et al 1998), it is plausible that estrogen protects 
the myocardium from β1-adrenergic receptor over-stimulation.  
This interaction between β1-adrenergic receptors and estrogen was confirmed in a 
study in which isoproterenol (a β1-adrenergic receptor agonist) was administered to 
ovariectomised rats (Kam et al 2003). β1-adrenergic receptor expression, density and affinity, 
cyclic AMP expression as well as infarct size (induced by LAD coronary artery ligation) 
were increased in ovariectomised rats. However, exogenous 17β-estradiol administration to 
ovariectomised rats suppressed these effects. In support of a role of estrogen in moderating 
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β1-adrenergic receptor responses, Vizgirda et al (2002) demonstrated increased β1-adrenergic 
receptor responses to isoproterenol in male rats compared to female rats. 
An important study confirming the interaction between adrenergic receptors and 
estrogen in vivo was that of Ciric and Susic (1980), in which the heart rate and blood 
pressures of female rats were determined at different stages of the estrus cycle. Female rats 
were assigned to one of 5 groups: group 1, female rats in proestrus; group 2, female rats in 
metestrus; group 3, ovarectomised rats receiving placebo; group 4, ovarectomised receiving 
estradiol; group 5, ovarectomised receiving progesterone. Measurements of heart rate and 
blood pressure were obtained before and after the injection of ISO. The results demonstrated 
no difference in baseline measurements (heart rate and blood pressure) between groups 1 and 
2, both groups had a positive inotropic response to ISO with an increase in heart rate 
however; rats in proestrus had higher heart rates in response to ISO and the effect of ISO on 
heart rates lasted longer as compared to rats in metestrus. In groups 3, 4 and 5, ISO produced 
a fall in blood pressure. Interestingly, ovarectomised rats receiving exogenous estradiol had 
lower resting heart rates compared to placebo and progesterone treated rats. After ISO 
administration all three groups had a positive inotropic response however, rats treated with 
estradiol had a greater increase in heart rate as compared to progesterone and placebo treated 
groups. In summary, rats in proestrus which correlates to peak estrogen concentrations and 
ovarectomised rats receiving exogenous estradiol had a greater inotropic response to ISO as 
compared to the other groups. The authors suggested that such a response could be due to an 
interaction between estrogen and β-adrenergic receptors in that estrogen enhances myocardial 
functioning. Moreover, the authors cautioned that this was a short term study and that long 
term estradiol administration could have produced a different response. However, this was 
one of the first studies to show the importance of the estrus cycle as well as a relationship 
between estrogen and β-adrenergic receptors. 
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Although research has focused on β1-adrenergic receptors there is evidence to suggest 
that   β2-adrenergic receptors also play a role in the myocardium. Gao et al (2003) explored 
the effect of β2-adrenergic receptor (β2-AR) overexpression in both genders and the 
subsequent influence on survival rate and myocardial function. The results demonstrated that 
survival was greatest in the WT mice compared to both gender overexpression groups. In 
addition, male transgenic mice had significantly lower survival rate compared to female β2-
AR overexpression mice, thus alluding to the fact that a gender difference does exist and that 
estrogen is cardioprotective. Moreover male transgenic mice had enlarged left ventricular 
dimensions, increased hypertrophy and dilatation compared to the female transgenic mice. 
The study also demonstrated increased amounts of fibrosis and apoptosis in the male 
transgenic mice compared to the other groups (WT and female transgenic mice). The 
researchers performed orchiectomy (removal of the testes) in the male transgenic mice and 
ovariectomised the female transgenic mice. Interestingly, male transgenic mice had increased 
survival rates compared to their female counterparts, and hence raises the questions whether 
testosterone is detrimental to the myocardium. Furthermore, whether estrogen is only 
cardioprotective in the early stages of a myocardial insult and not during chronic 
development also needs to be assessed.  In another study Xydas et al (2006) confirmed that a 
β2-AR agonist (clenbuterol) attenuated cardiomyocyte apoptosis and ventricular remodelling 
in LAD ligation induced heart failure. The latter effect was also noted in rats receiving a β1-
receptor antagonist (metoprolol), thus demonstrating the importance of the β1-receptor. 
In summary, the above studies (Gao et al 2003; Xydas et al 2006; Kam et al 2003; 
Wong et al 2007; Thawornkaiwong et al 2003; Vizgirda et al 2002) have clearly 
demonstrated that a relationship does exist between β1-adrenergic receptors and estrogen; 
however the effects of estrogen on the mechanisms of the detrimental effects of increased β1-
adrenoceptor stimulation warrant investigation. In this regard, the effects of estrogen on β1-
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adrenoceptor induced cardiomyocyte death (apoptosis or necrosis) and myocardial collagen 
production are not known. 
1.4 Cardiomyocyte apoptosis and necrosis 
Apoptosis, or programmed cell death, is a physiological process designed to remove 
dead or damaged cells and maintain a homeostatic environment. Apoptosis is controlled 
genetically by the activation of specific genes and enzymatic proteins (Dlamini et al 2004). 
Distinct morphological features of apoptosis are; cell shrinkage, peripheral chromatin 
condensation, DNA fragmentation, cytoplasmic “blebbing” and the formation of apoptotic 
bodies. Apoptotic bodies are recognised by specific immune cells and are removed without 
the induction of an inflammatory response (Dlamini et al 2004).  In contrast, necrosis is 
accidental cell death and results in dysregulation of the cell structure; that is cell swelling, 
rupturing of the plasma membrane, spillage of cellular contents, surrounding cell damage and 
the induction of an inflammatory response (Dlamini et al 2004; Jugdutt and Idikio 2000). 
Moreover, necrosis is closely associated with fibrosis. Weber and Brilla (1992) define 
fibrosis as an abnormal increase in collagen concentration which is either reactive, that is 
increased de novo collagen synthesis; or replacement, that is formation of scar tissue by 
replacement of necrotic myocytes. Both types of fibrosis negatively influence myocardial 
compliance (Bos et al 2004, Suzuki et al 2002).   
Current research demonstrates that increases in both cardiomyocyte apoptosis and 
necrosis occur in myocardial infarction and heart failure (Communal et al 1998). The 
consequences of increased apoptosis and necrosis are that viable, functioning cardiomyocytes 
are destroyed and consequently cardiac remodelling is induced (Francis 2000).   Prolonged 
cardiac remodelling results in myocardial dilatation, pump dysfunction and ultimately end 
stage heart failure (Cohn and Colucci 2006). An important question is therefore, what is 
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responsible for the increases in cardiomyocyte apoptosis and necrosis prior to end stage heart 
failure? 
It is well established that patients in heart failure present with increased levels of 
noradrenaline. The initial increase in noradrenaline is a compensatory effect to improve 
myocardial contractility and hence cardiac function; however prolonged stimulation of β-
adrenergic receptors induces severe myocardial remodelling and cardiac dilatation (Tan et al 
2004). Moreover, high levels of noradrenaline have been shown to induce cardiomyocyte 
apoptosis both in vitro (Communal et al 1998) and in vivo (Goldspink et al 2004) as well as 
cardiomyocyte necrosis (Goldspink et al 2004). The noradrenaline or ISO-induced increases 
in apoptotic cardiomyocytes were shown to be prevented by the pre-treatment of 
cardiomyocytes with the β-blocker, propanolol (Communal et al 1998). Three to six hours 
after the administration of high doses of ISO to rats, cardiomyocyte apoptosis was identified; 
whereas cardiomyocyte necrosis only occurred 18 hours after the administration of ISO 
(Goldspink et al 2004). Hence, excess stimulation of β-adrenergic receptors induces 
cardiomyocyte apoptosis and necrosis. 
1.4.1 Estrogen effects on cardiomyocyte apoptosis   
Bearing in mind the lower incidence of heart failure in premenopausal women 
compared to men, the effects of estrogen on cardiomyocyte apoptosis and necrosis have been 
investigated (Figure 2). Kim et al (2006) reported that 10nM estrogen prevented hypoxia-
induced apoptosis in cultured rat cardiomyocytes, an effect which was inhibited by an 
estrogen receptor antagonist.   Estrogen was shown to inhibit the activity of pro-apoptotic 
kinase p38α (Kim et al 2006), which is a crucial protein involved in the pro-apoptotic 
pathway. In addition, estrogen was shown to decrease apoptosis by enhancing the activity of 
kinase p38β which promotes cell survival (Kim et al 2006). The production of ROS (reactive 
oxygen species), which are potent stimulators of apoptosis, was also decreased by estrogen  
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Figure 2 Effects of estrogen on apoptotic signalling pathways 
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(Kim et al 2006). Although, this study clearly highlights the positive role estrogen plays in 
the inhibition of cardiomyocyte apoptosis; it fails to assess the effect of estrogen in an in vivo 
model which could present with different results as other physiological systems would be 
involved. 
Hence, in order to assess the effects of estrogen in an in vivo model, van Eickels et al 
(2003) performed a study using ovariectomised female mice receiving 17β-estradiol. Smaller 
myocardial infarctions (LAD coronary artery ligation) were observed after six weeks of 17β-
estradiol administration. However, the mice receiving 17β-estradiol had increased LV 
remodelling and mortality despite the smaller infarct sizes. Nevertheless, cardiomyocyte 
apoptosis was decreased in the ovariectomised mice receiving 17β-estradiol. In this study 
apoptosis was assessed by using the TUNEL technique as well as by determining the 
concentrations of caspase-3 (an enzymatic marker of apoptosis). These results are 
controversial as exogenous 17β-estradiol administration decreased myocardial infarct size as 
well as cardiomyocyte apoptosis but failed to prevent cardiac remodelling or to decrease 
mortality rates. Indeed, previous studies have demonstrated that 17β-estradiol is anti-
hypertrophic and decreases cardiac remodelling (Booth et al 2005; van Eickels  et al 2001; 
Pelzer et al 2005). Moreover, reductions in cardiomyocyte apoptosis (TUNEL and caspase-3) 
have been reported following 17β-estradiol administration to ovarietomised mice with MI 
induced by coronary artery ligation (Patten et al 2004). The Akt (serine-threonine kinase) 
pathway, which plays a crucial role in anti-apoptotic effects, was enhanced  at 24 and 72 
hours post-MI in the mice receiving 17β-estradiol versus the controls, an effect which was 
inhibited by an estrogen receptor antagonist (Patten et al 2004). This study further 
demonstrated that 17β-estradiol activated Akt through estrogen α-receptors and not through 
estrogen β-receptors. In contrast to the study performed by van Eickels et al (2003), Patten et 
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al (2004) demonstrated the protective effect of estrogen against cardiomyocyte apoptosis and 
caste some light into one of the specific apoptotic pathways mediating this effect.  
Although both van Eickels et al (2003) and Xydas et al (2006) reported a reduction in 
cardiomyocyte apoptosis due to estrogen, in both of these studies cardiomyocyte apoptosis 
was induced by LAD coronary artery ligation.  However, LAD coronary artery ligation is an 
extremely aggressive model, in that it induces very high percentages of cardiomyocyte 
apoptosis. Indeed, van Eickels et al (2003) reported cardiomyocyte apoptosis ranging from 
3.85% in control to 17.7% in LAD, and Xydas et al (2006) from 0.2% in control to 21% in 
LAD.   Importantly, a 0.2% increase in cardiomyocyte apoptosis per day, if sustained for a 
year, would result in a loss of half of the functioning cardiomyocytes and consequently 
severe myocardial damage would occur (Colucci 1996). Hence, high percentages of apoptosis 
are not physiologically compatible with normal or even compromised myocardial function. 
Therefore, LAD coronary artery ligation models are not likely to be representative of human 
heart failure.  In comparison to the high percentages of apoptosis reported only 6 weeks after 
LAD coronary artery ligation (van Eickels et al 2003; Xydas et al 2006); Veliotes et al 
(2005), in a model of heart failure induced by 4.5 months of ISO administration, 
demonstrated lower levels of apoptosis with percentages ranging from 1.99% in control to 
5.37% with ISO. Thus in comparison to the model of LAD coronary artery ligation, chronic 
ISO administration (Veliotes et al 2005) is more likely to mimic the natural progression of 
human heart failure. Nevertheless, in order to elucidate whether cardiomyocyte apoptosis is a 
cause or a consequence of chronic ISO-induced cardiac failure, the effects of short-term (~7 
days) ISO administration on cardiomyocyte apoptosis need to be assessed. Indeed Osadchii et 
al (2006) assessed the effects of short term ISO administration on cardiomyocyte apoptosis. 
The results demonstrated that 5 days of ISO induced 5.02% cardiomyocyte apoptosis 
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(Osadchii et al 2006). However, to date the effects of estrogen administration on short-term 
(~7 days) ISO administration on cardiomyocyte apoptosis have not been assessed.     
 
1.4.2  Estrogen effects on cardiomyocyte necrosis   
In addition to the effects of estrogen on cardiomyocyte apoptosis, the impact of 
estrogen on cardiomyocyte necrosis and replacement fibrosis has also been investigated. In 
ovariectomized rabbits receiving 17β-estradiol (which decreases cardiovascular mortality, see 
end of section 1.3.1.2, page 27 and Figure 1), infarct size (induced by LAD coronary artery 
ligation) was decreased in comparison to that of ovariectomized rabbits receiving 17α-
estradiol (which decreases apoptosis and myocardial infarction, see end of section 1.3.1.2, 
page 27 and Figure 1) or sham operated female rabbits (Booth et al 2001). The reduction in 
infarct size with 17β-estradiol was associated with the prevention of necrosis as determined 
by sarcomere and mitochondrial structure as well as decreased neutrophil accumulation in the 
affected infarct areas (Booth et al 2001).  Hence, estrogen, via stimulation of the estrogen β-
receptor, decreases infarct size and the degree of necrosis. 
Similarly, in a model of ischaemic-reperfusion injury, exogenous 17β-estradiol 
administration to ovariectomized rats reduced necrosis, neutrophil infiltration and oxygen 
free radicals (Jeanes et al 2008). However, in this study by Jeanes et al (2008) the beneficial 
effects attributed to estrogen were shown to be mediated by estrogen α-receptors and not 
estrogen β-receptors. Indeed, Hale et al (1996) demonstrated that ovariectomised female 
rabbits receiving exogenous 17β-estradiol after coronary occlusion, had smaller infarct sizes 
and decreased myocardial necrosis as compared to rabbits receiving placebo. Although the 
results are favourable, the concentrations of 17β-estradiol that were used were extremely high 
with levels of 392 pg.ml
-1
. Such concentrations fail to correlate with normal physiological 
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levels as described by other studies (Jang et al 2004). Hence, although these studies 
demonstrated that exogenous 17β-estradiol decreased necrosis in vivo in ovariectomized 
mice, the possible cardio-protective effects of estrogen released during the natural estrus 
cycle remain to be elucidated.  
The studies discussed above on the role of estrogen in cardiomyocyte apoptosis and 
necrosis have all been animal based. Hence, what is the evidence of estrogen mediated 
cardiomyocyte apoptosis or necrosis in human hearts. In myocardial samples, collected from 
male and female patients undergoing heart transplantations for heart failure, males had a 
twofold higher rate of cell death (both apoptosis and necrosis) than females (Guerra et al 
1999). In addition, the women were noted to have had a later onset of myocardial 
decompensation and an increased time frame between heart failure and the need for heart 
transplantation compared to the men (Guerra et al 1999). Although, this study revealed a 
gender difference in cardiomyocyte apoptosis and necrosis in humans; the women 
participants were aged 41-61 years old and whether they were pre- or post-menopausal or on 
HRT was not assessed.  It is plausible that estrogen played a role in the cardioprotection of 
the female hearts; however, in the context of the limitations of this study, it is crucial to 
investigate the possible physiological mechanisms that facilitate female cardioprotection. At 
present no studies have assessed the effects of estrogen on short term ISO-induced apoptosis 
and necrosis and further research is required to elucidate whether estrogen can decrease β- 
adrenergic induced cardiomyocyte apoptosis and necrosis. 
 
1.5 The relationship between estrogen, β-adrenergic receptors and 
apoptosis/necrosis 
A relationship between increased β-adrenergic stimulation and cardiomyocyte 
apoptosis/necrosis, and the subsequent damaging effects on the myocardium (cardiac 
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dilatation and heart failure progression) has been demonstrated (Communal et al 1999). In 
addition, estrogen receptors are located in the myocardium and research has revealed the 
beneficial effects of estrogen therapy on myocardial induced insults (Booth et al 2005; Van 
Eickels et al 2001; Pelzer et al 2005). Moreover, studies have confirmed that estrogen down 
regulates the action of β-adrenergic receptors within the myocardium (Thawornkaiwong et al 
2002). Studies have also revealed that estrogen decreases cardiomyocyte apoptosis and 
necrosis induced by hypoxic reperfusion (Kim et al 2006). However, at present no study has 
examined whether estrogen can attenuate β-adrenergic induced cardiomyocyte apoptosis or 
necrosis in vivo. Moreover, the effects of the natural estrus cycle on increased β-adrenergic 
stimulation, a potent catalyst of myocardial damage and heart failure, have not been assessed. 
Thus it is crucial to evaluate whether estrogen is cardioprotective due to possible inhibitory 
effects on β-adrenergic activation and a subsequent reduction in apoptosis and necrosis. 
 It is also important to note that currently the studies that have been performed have 
used ovariectomized female animals receiving exogenous estrogen, knockout or over 
expression of estrogen receptors (either β or α receptors) or cell cultures. Although the studies 
have yielded constructive results these animal models fail to assess the natural estrus cycle. In 
addition in models of females receiving exogenous estrogen, physiological levels are 
exceeded and the fluctuations during the normal estrus cycle are eliminated. Thus, although a 
relationship has been established between estrogen and β-adrenergic receptors as well as 
cardiomyocyte apoptosis/necrosis and β-adrenergic receptors, whether estrogen is 
cardioprotective through decreasing β-adrenergic induced apoptosis and necrosis is unknown. 
1.6 Summary and study objectives  
In summary, the results from human studies are inconsistent. Some studies demonstrate 
beneficial effects of HRT such as decreasing atherosclerotic plaque progression, improving 
the lipid profile (Manson et al 2007), reducing the risk of myocardial infarctions (Varas-
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Lorenzo et al 2000) and coronary artery disease (Grady et al 1992). On the contrary, other 
studies reveal harmful effects of HRT namely; increased risk of breast cancer, coronary heart 
disease and pulmonary emboli (Hulley et al 1998; Roussow et al 2002). Moreover, there are 
variations between the human studies with respect to their study designs and the 
characteristics of the participants. In addition, treatment regimens for HRT vary between 
studies such as the duration of administration, route of administration (tablets or transdermal), 
dosages, and the combination of hormones (estrogen only or estrogen plus progesterone). 
Though, the general consensus from human studies is that estrogen rather than progesterone 
is the cardioprotective hormone (Grady et al 1992, Varas-Lorenzo et al 2000, Manson et al 
2007). Nevertheless, data shows that males have a higher risk of cardiovascular disease than 
females prior to menopause, after which the gender discrepancy in risk of cardiovascular 
disease is diminished (Hulley et al 1998; Rossouw et al 2002). Therefore, it is essential to 
explore the potential cardioprotective effects of estrogen and the physiological mechanisms 
thereof. For the latter to be achieved animal studies are required.  
Although, to date numerous animal studies have demonstrated beneficial effects of 
estrogen, such as decreases in infarct size (Booth et al 2003), cardiac fibroblast growth 
(Dubey et al 1998), apoptosis/necrosis (Kim et al 2006), heart rate (Ueyama et al 2007) and 
myocardial hypertrophy (Van Eickels et al 2001), these studies have certain limitations. 
Firstly, the animal models (e.g. transverse aortic ligation, immobilization stress models, left 
coronary artery ligation and hypoxic re-oxygenation) used to induce myocardial damage are 
extremely aggressive and hence fail to mimic the natural progression of cardiac failure.  
Secondly, cell cultures rather than intact animals are often used and hence the data fail to 
assess the interaction of all physiological systems, therefore rendering the results unlikely to 
represent data obtained in an in vivo model. Thirdly, the majority of in vivo studies have 
investigated the effects of exogenous estrogen administration to ovariectomized female 
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animals. The limitations of exogenous estrogen administration are the high non-physiological 
concentrations of estrogen that are used, as well as the loss of the normal cyclical fluctuations 
of estrogen during the estrus cycle. Indeed, the benefits versus risks of estrogen are dependent 
on the concentration administered (Varas-Lorenzo et al 2000), with higher concentrations 
conferring less benefit (Varas-Lorenzo et al 2000). 
To address the three limitations discussed above, I chose to study an in vivo model 
which more closely mimics the natural slow progression of heart failure, namely daily ISO 
administration, in naturally cycling female compared to male rats. In order to identify 
mechanisms it is imperative to assess early markers of cardiac dysfunction, hence I chose to 
assess apoptosis and necrosis/fibrosis as my primary outcomes.   
Hence, the aim of my study was to assess the impact of gender on short term β-
adrenergic induced cardiomyocyte apoptosis and necrosis/fibrosis in rats in vivo. 
The specific objectives of my study were to assess: 
 the impact of short term (5 days) β-adrenergic receptor activation on cardiomyocyte 
apoptosis in naturally cycling female WKY rats during peak estrogen concentrations 
compared to male WKY rats 
 the impact of short term (5 days) β-adrenergic receptor activation on cardiomyocyte 
necrosis/fibrosis in naturally cycling female WKY rats during peak estrogen 
concentrations compared to male WKY rats 
 the impact of short term (5 days) β-adrenergic receptor activation on cardiac 
function in naturally cycling female WKY rats during peak estrogen concentrations 
compared to male WKY rats 
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 the impact of short term (5 days) β-adrenergic receptor activation on cardiac 
geometry in naturally cycling female WKY rats during peak estrogen concentrations 
compared to male WKY rats 
 the impact of short term (5 days) β-adrenergic receptor activation on acute 
responses to β-adrenergic receptor activation in naturally cycling female WKY 
rats during peak estrogen concentrations compared to male WKY rats 
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Chapter 2 
Materials and Methods 
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2 Materials and methods 
A summary of the materials and methods used in this study is illustrated in Figure 3. 
2.1 Groups and treatment regimen 
All experimental procedures were approved by the Animal Ethics Screening 
Committee of the University of the Witwatersrand (AESC 2007/28/04). A total of 27 male 
and 29 female age-matched (2 month old) Wistar-Kyoto (WKY) rats were assigned to one of 
four groups. The four groups were named according to the regimen administered namely; 
daily subcutaneous injection of a β-adrenergic agonist isoproterenol [ISO (SIGMA-
ALDRICH, South Africa); 0.02mg.
-1
kg.
-
1.day
-1
 administered in 0.2ml saline]; isoproterenol 
male (ISO M, n=14); isoproterenol female (ISO F; n=15) and daily subcutaneous injection of 
vehicle (saline, 0.2ml), control female (CON F, n=14) and control male (CON M, n=13). The 
isoproterenol or saline was administered for a period of 5 days. On the fifth day, rats were 
weighed and then anaesthetised with ketamine (Anaket, 75mg.kg
-1
, Centaur Labs, South 
Africa) and xylazine (Chanazine, 15mg.kg
-1
, Centaur Labs, South Africa)  and 
echocardiography was performed to assess the effects of ISO administration on cardiac 
geometry and function (see 2.3 below).  
As the primary aim of my study was to assess gender differences and more specifically, 
the effects of natural estrogen (estrogen concentrations in a natural estrus cycle) on 
cardiomyocyte apoptosis and necrosis, female rats were terminated at the peak of estrogen 
concentrations, in other words during proestrus (Marcondes et al 2002; Kramer and Bellinger 
et al 2009). Hence, the timing of the commencement of isoproterenol or saline administration 
had to be considered. The normal rat estrus cycle lasts approximately four to five days and 
consists of various stages. The four stages are proestrus, estrus, metestrus and diestrus. 
Estrogen concentrations start increasing in metestrus, peak during proestrus and return to  
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Figure 3: Summary of the materials and methods.  
ISO, isoproterenol; F, female; LV, left ventricle; M, male; WKY, Wistar-Kyoto 
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baseline in estrus. In order to ensure termination of the female rats at peak estrogen 
concentrations (proestrus), isoproterenol or saline administration had to commence in estrus. 
Vaginal smears were therefore performed to assess the stage of estrus (see 2.2 below) prior to 
the commencement of isoproterenol or saline administration. The reason for using two month 
old rats are as follows:  female rats start cycling at about six weeks of age, thus two month 
old female rats were used with aged matched male rats. The youngest age of termination was 
approximately three months of age therefore ensuring that rats were in a “pre-menopausal” 
state. Female rats stop cycling at about twelve months of age (Marcondes et al 2002) and are 
then considered to be in a “post-menopausal” state.     
2.2 Vaginal smears 
The four stages of the rat estrus cycle, namely proestrus, estrus, metestrus and diestrus 
last twelve, twelve, twenty one and sixty hours respectively, hence the estrus cycle lasts a 
total of 4 days and 19 hours (Marcondes et al 2002). The stage of diestrus was further 
subdivided into early and late diestrus. Each phase is characterised by specific vaginal 
epithelial cells that can be distinguished using light microscope (Marcondes et al 2002). 
Proestrus has round nucleated epithelial cells; estrus has large cornified, anucleated epithelial 
cells; metestrus has large cornified and elongated epithelial cells as well as small round 
leucocytes; early diestrus has only small leucocytes and late diestrus has small leucocytes as 
well as some round nucleated epithelial cells (Figure 4). To assess each stage of estrus, the 
rats were restrained manually (hand placed over back of rat) and the tail and hind legs 
elevated to expose the vaginal orifice.  
A plastic dropper containing saline was inserted into the vagina and the cervix was 
washed several times to remove vaginal surface cells. The dropper was then used to aspirate  
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Figure 4: Representative examples of vaginal smears representing the four stages of the 
rat oestrus cycle.  
A, Proestrus - round nucleated epithelial cells (a); B, Estrus - large cornified, anucleated 
epithelial cells (d); C, Metestrus - large epithelial cells (a), elongated epithelial cells (b) and a 
few leucocytes (c) ; D, Early Diestrus - many leucocytes (c); E, Late Diestrus - leucocytes (c) 
and a few nucleated epithelial cells (a). 
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saline containing vaginal surface cells. Once aspirated a drop of saline containing vaginal 
cells was placed on a slide and viewed instantly under a light microscope at 40X 
magnification. As peak estrogen concentrations occur during proestrus, to ensure that female 
rats were terminated when estrogen levels were at their peak, ISO or saline injections were 
started at estrus, which is approximately five days before proestrus. Vaginal smears were 
performed daily and once rats were cycling normally and together, ISO or saline injections 
were commenced at estrus. 
 
2.3  Echocardiography 
Echocardiography was performed to assess the effects of five days of ISO or saline 
administration on cardiac geometry and function in vivo in male versus female rats, as well as 
the effects of acute ISO or saline administration on cardiac function and geometry. The 
assessments of the acute effects served to confirm that the dose of ISO administered was 
sufficient to induce a positive inotropic response (increased contractility).  
On the fifth day, rats were anesthetised with ketamine (Anaket, 75mg.kg
-1
, Centaur 
Labs, South Africa) and xylazine (Chanazine, 15mg.kg
-1
, Centaur Labs, South Africa) to 
ensure immobilisation. Two sets of echocardiography measurements were made, the first to 
assess the effects of five days of ISO or saline administration on cardiac geometry and 
function in male and female rats. The second sets of measurements were made after an 
injection of ISO or saline according to the group specification. In other words, ISO M and 
ISO F received a subcutaneous injection of ISO (0.02mg.kg
-1
 administered in 0.2ml saline) 
and CON M and CON F received a subcutaneous injection of saline (0.2ml). To allow for 
adequate responses to ISO or saline to occur, the second set of measurements were made at 
least 30 minutes after ISO or saline administration.  
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Echocardiography is a non-invasive technique which entails placing a high resolution 
probe on the chest wall of the rats and obtaining a two-dimensional guided M-mode image of 
the heart (7.5 MHz transducer, Siemens Medical Solutions, Mountain View, California, 
USA). By imaging the left ventricle in the short axis, images of the left ventricular 
dimensions and posterior wall thickness were acquired and used to assess left ventricular 
geometry and both chamber and myocardial systolic function (Norton et al 1997; Tsotetsi et 
al 2001; Woodiwiss et al 2001). From the images acquired measurements of left ventricular 
end diastolic diameter (EDD), left ventricular end systolic diameter (ESD), posterior wall  
thickness at end-diastole (PWTd), and posterior wall thickness at end-systole (PWTs) were 
made (Figure 5). These measurements were used to assess changes in left ventricular 
geometry in response to ISO or saline in male and female rats. In addition, in order to assess 
the degree of ventricular concentricity, chamber diastolic area (Area) and relative wall 
thickness (RWT) were calculated using standard formulae (see below).  
To determine the effects of ISO or saline on chamber and myocardial systolic 
function in male and female rats, left ventricular endocardial fractional shortening (FSend) 
and left ventricular myocardial fractional shortening (FSmid) were calculated from the 
measurements of EDD, ESD, PWTd and PWTs, using standard echocardiographic formulae 
(Sahn et al 1978) (see below). In addition, to determine the effects of ISO and saline on heart 
rate in male and female rats, heart rate was calculated using a standard formula (see below). 
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Figure 5: Representative example of M-mode echocardiographic images of the left 
ventricle before (1) and after (2) isoproterenol administration. 
A, left ventricular end diastolic diameter (LVEDD); B, left ventricular end systolic diameter 
(LVESD); C, posterior wall thickness in diastole (PWTd); D, posterior wall thickness in 
systole (PWTs); E, cardiac cycle duration (R-R interval) used to calculate heart rate.   
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2.4 Heart weights and blood removal 
After all of the echocardiographic data had been obtained, a midline thoracotomy was 
performed after a second dose of ketamine and xylazine. The chest cavity was opened, the 
heart was rapidly excised and then placed in cold 0.9% saline.  
The heart tissue was washed in the cold saline, excess tissue and fat were removed and 
the heart tissue was blotted dry. The whole heart was then weighed. The right ventricular free 
wall was then removed and weighed, and then the left ventricular free wall and septum were 
weighed. In order to correct for differences in body weights between the male and female 
rats, whole heart, left and right ventricular weights were also calculated per 100g body 
weight. 
A longitudinal slice of the left ventricular free wall from the apex to the base was cut 
and placed in 4% formaldehyde (methanol free, 37% formaldehyde) in phosphate buffered 
saline (mmol.L
-1
) NaCl 137; KCL 2.7; Na2HPO4 8; KH2PO4 1.5 at pH 7.4, for histological 
analyses (see 2.7 below).  
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2.5 Blood sampling 
Immediately after extirpation of the heart, blood within the chest cavity was syringed 
and placed in evacuated tubes with no additives. The tubes were centrifuged and serum was 
removed and stored for later analysis of estrogen concentrations (see 2.6 below). The blood 
was removed from the chest cavity after removal of the heart, rather than directly from the 
heart via cardiac puncture, as the latter would have been likely to cause trauma to the heart 
which itself may induce cardiomyocyte apoptosis or necrosis.   
2.6  ELISA estrogen concentrations 
To confirm that the female rats were terminated at peak estrogen concentrations during 
proestrus, and to confirm that the male rats had lower estrogen concentrations compared to 
the female rats, serum estrogen concentrations were determined using an enzyme-linked 
immunosorbent assay (ELISA; DRG estradiol ELISA EIA-2693, Germany).  This assay 
works on the principle of competitive binding. The serum samples were mixed with an 
estradiol horseradish peroxidise conjugate and then pipetted in duplicate into a microtiter 96 
well plate which was coated with estrogen specific antibodies. These estrogen specific 
antibodies bind to the antigenic site of the estrogen molecule. Hence the serum sample and 
the estradiol horseradish peroxidase conjugate both compete for binding to the estrogen 
specific antibodies. After incubation the unbound conjugates were washed off. The amount of 
peroxidase conjugate that is bound to the antibodies is reverse proportional to the amount of 
estradiol in the sample.  A substrate solution was then added to each well, which produces an 
enzymatic reaction and hence a colour reaction to occur. A stop solution was subsequently 
added, which stopped the enzymatic reaction. The optical density (absorbance) was then read 
at a wavelength of 450±10nm using a microtiter plate reader, within 10 minutes of adding the 
stop solution. The intensity of the colour is inversely proportional to the concentration of 
estradiol in the sample. A standard curve was constructed with absorbance values on the Y-
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axis and concentration on the X-axis. The standard curve (see Figure 6) was used to 
determine the concentration of estrogen in each of the serum samples.   
 
2.7 Histological techniques 
The longitudinal slice of left ventricle that had been placed in 4% formaldehyde was 
embedded in paraffin wax. Histological sections (5µm thick) were then cut using a 
microtome and mounted onto slides prior to the various histological staining techniques (see 
2.7.1 and 2.7.2 below).   
2.7.1 TUNEL staining - cardiomyocyte apoptosis 
2.7.1.1 Principle 
Apoptosis was detected using a DeadEnd colormetric TUNEL system (Promega, 
South Africa) which works on the principle of DNA fragmentation. Briefly slides were 
dehydrated through a series of alcohol solutions and the tissues were primed for the staining 
technique. The tissues were permeabilized with proteinase K and labelled with biotinylated  
nucleotide mix which binds to the fragmented DNA in the presence of terminal 
deoxynucleotidyl transferase (TDT) enzyme. Subsequently streptavidin/horseradish 
peroxidase was added to bind to the biotinylated nucleotides.  Finally the tissues were stained 
with the peroxidise substrate, hydrogen peroxide and chromogen diaminobenzidine which 
enables the apoptotic nuclei to be viewed under a light microscope (apoptotic nuclei appear 
brown) (Figure 7D) (Agarwala and Kalil 1998). The cardiomyocyte nuclei were easily 
identified due to their characteristic large size, cigar shape and speckled brown appearance 
(Figure 7B, cells labelled a). In comparison the fibroblasts nuclei and nuclei of other tissue 
cells were small and stained a solid dark brown (Figure 7B, cells labelled b). 
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Figure 6: Standard curve used to calculate serum estrogen concentrations in samples. 
 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A, H & E stained section, a indicates cardiomyocyte nuclei, b indicates fibroblast or other 
nuclei; B, TUNEL positive tissue section indicating numerous apoptotic nuclei, a indicates 
cardiomyocyte nuclei, b indicates fibroblast or other nuclei; C, TUNEL negative tissue 
section with few visible nuclei; D, enlarged section of rat myocardium showing the presence 
of apoptotic cardiomyocyte nuclei (a) stained a speckled orange brown colour and 
fragmented around the edges.  
Figure 7: Representative examples of cardiac tissues sections stained with haemotoxylin 
and eosin (A), and TUNEL (B, C and D). 
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Positive and negative control slides were stained to ensure that the TUNEL assay 
worked effectively and did not produce false results. Briefly, the positive control slides had 
an additional step in which the slides were incubated in DNAse enzyme which breaks down 
DNA and hence produces DNA fragments as found in apoptotic nuclei. Thus the biotinylated 
nucleotide mix in the presence of TDT enzyme binds to all or the majority of nuclei in the 
tissue section. Hence the positive control slides demonstrated a majority of brown apoptotic 
nuclei as shown in Figure 7B. On the other hand, the negative control slides did not receive 
the TDT enzyme, hence preventing the binding of the biotinylated nucleotide mix to any 
fragmented DNA. Thus the negative control slides demonstrated no brown apoptotic nuclei 
(Figure 7C). 
2.7.1.2 Calculation of apoptotic nuclei 
The extent of cardiomyocyte apoptosis per tissue section was expressed as a percentage. In 
order to calculate the percentage of cardiomyocyte apoptosis, the total number of 
cardiomyocyte nuclei needed to be quantified. The latter was done by staining tissue sections 
with haematoxylin and eosin (H&E) and counting the number of cardiomyocyte nuclei in ten 
evenly spaced fields, from apex to base, at 400x magnification using a computer based image 
acquisition and analysis system (Nikon ACT2U imaging software, Nikon Corporation 2004, 
version 1.0.0.117). The number of apoptotic nuclei stained using the TUNEL technique 
(described above) were counted and expressed as a percentage of the total number of H&E 
cardiomyocytes (Figure 7A) per tissue section (see formula below). The cardiomyocyte 
nuclei were easily identified from their characteristic large size, cigar shape and speckled pale 
blue appearance (Figure 7A, cells labelled a), compared to the fibroblast nuclei and the nuclei 
of other cardiac tissue cells which were small and stained a solid dark blue (Figure 7A, cells 
labelled b). In addition, the cardiomyocyte nuclei were mostly located centrally within the 
cytoplasm of the cardiomyocytes (Figure 7A, cells labelled a).   
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2.7.2 Van Gieson’s staining - cardiomyocyte necrosis and fibrosis 
In order to assess necrosis and fibrosis, sections were stained with Van Gieson’s stain. 
Slides were viewed at 10X magnification and the amount of “pink” fibrosis was qualitatively 
analysed. Briefly a double-blinded observer assessed the percentage of “pink stained” fibrosis 
and necrosis (Figure 8A and C) in relation to the “green stained” myocardial tissue (Figure 
8B and D) throughout the slide and a pathological score was assigned. The pathological 
scoring as modified from Teerlink et al (1994) was as follows: 0 indicated no 
necrosis/fibrosis, 1 and 2 indicated patchy necrosis/fibrosis in <20% and > 20% of the field 
respectively, 3 and 4 indicated diffuse subendocardial necrosis/fibrosis in <50% and >50% of 
the field respectively and 5 and 6 indicated full thickness necrosis/fibrosis in <50% and 
>50% of the field respectively.  
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A, tissue section from an ISO male, the arrow indicates large amounts of dispersed 
necrosis/fibrosis throughout the section; B, tissue section from a CON male with no 
necrosis/fibrosis; C, tissue section from an ISO female, the arrow indicates a small portion of 
necrosis/fibrosis; D, tissue section from a CON female indicating no necrosis/fibrosis; 
arrows, collagen stains pink and indicates nerosis/fibrosis; the cytoplasm of the cardiac tissue 
cells are stained light green. 
  
Figure 8: Representative myocardial tissue sections stained with Van Gieson’s stain for 
necrosis and fibrosis. 
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2.8 Statistical analysis 
A two-way (regimen and gender) ANOVA was used to determine the effects of 5 days 
of ISO or saline administration, gender effects and gender-regimen interaction on body 
weight, heart weight, left and right ventricular weights, and cardiomyocyte apoptosis. Tukey-
Kramer post hoc analysis was performed following significant F values on ANOVA. A 
Kruskal-Wallis rank sum test determined differences between the groups for necrosis/fibrosis 
as this data was non-parametric. To determine the effects of 5 days of ISO or saline 
administration, as well as the effects of acute administration of ISO or saline, on cardiac 
function and geometry, a two-way (regimen and gender) repeated measures (baseline and 
after acute ISO or saline) ANOVA was performed. Tukey-Kramer post hoc analysis was 
performed following significant F values on ANOVA. An unpaired t-test was used to 
calculate the differences in estrogen concentrations. The statistical programs used were SAS 
software, version 9.1 (SAS institute Inc., Cary NC) and Instat (Graphpad Instat version 3.00, 
32 bit for win95/NT, 1997). Data were expressed as x±sem and P<0.05 was considered 
significant. 
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3 Results 
3.1 Body and heart weights 
The body weights of the two groups of male rats were significantly greater (p<0.001) 
than those of the two groups of female rats (Table 3). Consequently, the heart, left ventricular 
and right ventricular weights were greater in the two groups of male rats compared to the 
weight of the two groups of female rats (Table 3). Hence, comparisons of heart, left 
ventricular and right ventricular weight were also made after these weights had been adjusted 
to 100g body weight. Five days of isoproterenol administration had no effect on the body 
weights of either the male or the female rats (Table 3). In the male rats, 5 days of 
isoproterenol resulted in increased (p<0.001) heart, left ventricular and right ventricular 
weight, an effect not observed in the female rats. However, when assessing heart and left 
ventricular weights adjusted to 100g body weight; increases (p<0.01) in heart and left 
ventricular weight were observed after 5 days of isoproterenol administration in both the 
male and the female rats (Table 3).  An isoproterenol induced increase (p<0.01) in right 
ventricular weight adjusted to 100g body weight was observed in the male rats but only when 
compared to the female rats receiving saline (Table 3). 
3.2 Echocardiography data 
As a consequence of anaesthetic related deaths (1 rat from the ISO F group; 1 rat from 
the CON M group and 3 rats from the ISO M group), echocardiography data could not be 
obtained in these rats. Hence the samples sizes for the echocardiography data are: CON F= 
14; ISO F=14; CON M=12; ISO M=11.  
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Table 3: Effects of 5 days of isoproterenol administration on body, heart, left and 
right ventricular weights in male and female rats 
 
 CON F 
(n=14) 
ISO F 
(n=15) 
CON M 
(n=13) 
ISO M 
(n=14) 
 
Body weight (g) 
 
233.79±16.92 
 
228.33±23.05 
 
317.00±27.67* 
 
312.60±37.99* 
 
Heart weight (g) 
 
Heart weight/ 
100g body weight 
 
0.66±0.04 
 
 
0.28±0.02 
 
0.74±0.07 
 
 
0.33±0.04‡ 
 
0.90±0.10* 
 
 
0.28±0.03 
 
1.02±0.11*† 
 
 
0.33±0.02‡ 
 
LV weight (g) 
 
LV weight/ 
100g body weight 
 
0.52±0.05 
 
0.22±0.02 
 
0.59±0.05 
 
0.26±0.04‡ 
 
0.70±0.10* 
 
0.22±0.02 
 
 
0.79±0.10*† 
 
0.25±0.01‡ 
     
RV weight (g) 
 
RV weight/ 
100g body weight 
0.13±0.02 
 
0.06±0.01 
0.15±0.02 
 
0.06±0.01 
0.19±0.03* 
 
0.06±0.01 
0.23±0.05*† 
 
0.07±0.02** 
 
*P <0.001 vs. CON F and ISO F; **P<0.01 vs. CON F; ‡ P<0.01 vs. CON M and CON F; 
†P<0.001 vs. CON M 
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3.2.1 Heart rate 
The two-way repeated measures ANOVA demonstrated a gender effect (p<0.05), a 
regimen effect (p<0.0001), a time effect (p<0.0001), a time-regimen interaction (p<0.0001), a 
gender-regimen interaction (p<0.05) and a time-regimen-gender interaction (p=0.004). On 
post-hoc analysis, a gender difference was noted, with both groups of male rats having higher 
heart rates (p<0.05) than the two groups of female rats at baseline (B) and after saline 
administration (Figure 9). Five days of isoproterenol administration had no effect on heart 
rates in either the male or the female rats (p=0.995, comparison of heart rates at baseline, B; 
Figure 9). However, acute administration of isoproterenol; but not saline, increased heart rate 
in both the male (p<0.005) and the female (p<0.0001) rats (after, A; Figure 9). Moreover, the 
increment in heart rate observed in response to acute isoproterenol in the female rats was 
greater than that observed in the male rats (increase in heart rate in females: 144.2±5.5 
bts/min; males: 103.1±18.2bts/min; p<0.05). 
3.2.2 Left ventricular endocardial fractional shortening 
On two-way repeated measures ANOVA, a time effect (p<0.0001), a regimen effect 
(p<0.0001) and a time-regimen interaction (p<0.0001) were demonstrated. Post-hoc analysis, 
revealed an effect of acute administration of isoproterenol in both the male and the female 
rats (Figure 10). No gender related differences were observed in endocardial fractional 
shortening (Figure 10). Similarly, 5 days of isoproterenol administration had no effect on 
endocardial fractional shortening in either the male or the female rats (Figure 10; at baseline, 
B). Importantly, however acute isoproterenol administration induced an increase (p<0.0001) 
in endocardial fractional shortening in both male and female rats (Figure 10; after, A), 
consistent with a positive inotropic response. Acute saline administration, as expected, had no 
effect on endocardial fractional shortening. The positive inotropic effect was similar between  
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B=before (baseline) an injection of saline (CON F and CON M, hatched bars) or 
isoproterenol (ISO F and ISO M, hatched bars); A=after an injection of saline (CON F and 
CON M, cross-hatched bars) or isoproterenol (ISO F and ISO M, cross-hatched bars); # 
p<0.05 vs corresponding male group; * p<0.005, ISO M after isoproterenol injection vs. ISO 
M before, CON M (before and after), CON F (before and after), and ISO F before; † 
p<0.0001, ISO F after isoproterenol injection vs. ISO F before, CON M (before and after), 
CON F (before and after), and ISO M before. 
  
Figure 9:  Effects of gender, 5 days of isoproterenol or saline administration and acute 
administration of isoproterenol or saline on heart rates in male and female rats.  
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B=before (baseline) an injection of saline (CON F and CON M, hatched bars) or 
isoproterenol (ISO F and ISO M, hatched bars); A=after an injection of saline (CON F and 
CON M, cross-hatched bars) or isoproterenol (ISO F and ISO M, cross-hatched bars); * 
p<0.0001, ISO M after isoproterenol injection vs. ISO M before, CON M (before and after), 
CON F (before and after), and ISO F before; † p<0.0001, ISO F after isoproterenol injection 
vs. ISO F before, CON M (before and after), CON F (before and after), and ISO M before.  
 
Figure 10:  Effects of gender, 5 days of isoproterenol or saline administration and acute 
administration of isoproterenol or saline on endocardial fractional shortening in male 
and female rats. 
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the male and the female rats (change in FSend in males: 13.3±2.0%; females: 12.7±2.2%; 
p>0.05). 
3.2.3 Left ventricular midwall fractional shortening 
Two-way repeated measures ANOVA of left ventricular midwall fractional 
shortening data revealed a time effect (p=0.01), a regimen effect (p<0.05) and a time-regimen 
interaction (p=0.01). At baseline no gender differences in left ventricular midwall fractional 
shortening were noted (Figure 11; at baseline, B). Moreover, 5 days of isoproterenol 
administration had no effect on left ventricular midwall fractional shortening in male or 
female rats (Figure 11; at baseline, B). Acute isoproterenol produced significant increments 
in left ventricular midwall fractional shortening in male and female rats (Figure 11; after, A), 
which are consistent with the positive inotropic effects of isoproterenol. As expected, acute 
saline administration did not alter left ventricular midwall fractional shortening in male or in 
female rats (Figure 11; after A). The increments in left ventricular midwall fractional 
shortening were no different in the male compared to the female rats (change in FSmid in 
males: 3.9±1.6%; females: 4.1±2.0%; p>0.05). 
3.2.4 Left ventricular end diastolic diameter, chamber area and relative wall 
thickness 
Analysis of left ventricular end diastolic diameters revealed a regimen effect 
(p<0.0001), a gender effect (p<0.001), a time effect (p<0.0001) and a time-regimen 
interaction (p<0.0001). At baseline significant gender differences were noted, with the male 
rats having greater (p<0.0001) left ventricular end diastolic diameters compared to the female 
rats (Figure 12). These gender differences in left ventricular end diastolic diameter could be 
attributed to the fact that the male rats were larger and hence had heavier heart weights 
compared to the female rats (Table 3). Five days of isoproterenol administration had no effect 
on left ventricular end diastolic diameters in either male or female rats; however acute  
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B=before (baseline) an injection of saline (CON F and CON M, hatched bars) or 
isoproterenol (ISO F and ISO M, hatched bars); A=after an injection of saline (CON F and 
CON M, cross-hatched bars) or isoproterenol (ISO F and ISO M, cross-hatched bars); * 
p<0.05, ISO M after isoproterenol injection vs. ISO M before, CON M (before and after), 
CON F (before and after), and ISO F before; † p<0.05, ISO F after isoproterenol injection vs. 
ISO F before, CON M (before and after), CON F (before and after), and ISO M before.  
 
 
Figure 11: Effects of gender, 5 days of isoproterenol or saline administration and acute 
administration of isoproterenol or saline on left ventricular midwall fractional shortening 
in male and female rats. 
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B=before (baseline) an injection of saline (CON F and CON M, hatched bars) or 
isoproterenol (ISO F and ISO M, hatched bars); A=after an injection of saline (CON F and 
CON M, cross-hatched bars) or isoproterenol (ISO F and ISO M, cross-hatched bars); # 
p<0.001 vs. males; * p<0.0001, ISO M after isoproterenol injection vs. ISO M before, CON 
M (before and after), CON F (before and after), and ISO F before; † p<0.0001, ISO F after 
isoproterenol injection vs. ISO F before, CON M (before and after), CON F (before and 
after), and ISO M before. 
Figure 12: Effects of gender, 5 days of isoproterenol or saline administration and acute 
administration of isoproterenol or saline on left ventricular end diastolic diameter in 
male and female rats. 
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isoproterenol, but not saline, resulted in a decrease (p<0.0001) in left ventricular end diastolic 
diameter indicative of a positive inotropic effect (Figure 12). The decrease in end diastolic 
diameter observed in the male rats was no different from that observed in the female rats 
(change in EDD, males: -1.17±0.22mm; females: -1.24±0.13mm).   
Consistent with the greater end diastolic diameters observed in the male rats 
compared to the female rats, left ventricular chamber diastolic areas were larger (p<0.05) in 
the male rats compared to the female rats (Figure 13 upper panel). However, even after left 
ventricular chamber areas had been adjusted to 100g body weight, the male rats had larger 
(p<0.05) left ventricular chamber diastolic areas than the female rats (Figure 13 lower panel). 
Hence, the increased chamber dimensions observed in the male rats are probably more likely 
due to a greater degree of dilatation (eccentricity) in male rats compared to female rats. 
Indeed, the relative wall thickness was decreased (p<0.05) in the male rats compared to the 
female rats (Figure 14).  
Five days of isoproterenol had no effect of LV diastolic chamber area (p<0.0001); but 
in response to acute isoproterenol similar positive inotropic effects (p<0.0001) were observed 
in male and female rats (Figure 13). Five days of isoproterenol, however resulted in increases 
in relative wall thickness in both male and female rats (Figure 14), consistent with the 
isoproterenol-induced increments in LV weight/100g body weight (Table 3). In addition, 
increases in relative wall thickness were observed in response to acute isoproterenol in both 
the male and the female rats (Figure 14). 
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B=before (baseline) an injection of saline (CON F and CON M, hatched bars) or  
 
A=after an injection of saline (CON F and CON M, cross-hatched bars) or isoproterenol (ISO 
F and ISO M, cross-hatched bars); # p<0.05 vs. males; * p<0.0001, ISO M after isoproterenol 
injection vs. ISO M before, CON M (before and after), CON F (before and after), and ISO F 
before; † p<0.0001, ISO F after isoproterenol injection vs. ISO F before, CON M (before and 
after), CON F (before and after), and ISO M before. 
 
Figure 13: Effects of gender, 5 days of isoproterenol or saline administration and acute 
administration of isoproterenol or saline on left ventricular diastolic chamber area in 
male and female rats. 
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B=before (baseline) an injection of saline (CON F and CON M, hatched bars) or 
isoproterenol (ISO F and ISO M, hatched bars); A=after an injection of saline (CON F and 
CON M, cross-hatched bars) or isoproterenol (ISO F and ISO M, cross-hatched bars); # 
p<0.05 vs. corresponding male group; * p<0.001, ISO M after isoproterenol injection vs. ISO 
M before, CON M (before and after), CON F (before and after), and ISO F before; † p<0.001, 
ISO F after isoproterenol injection vs. ISO F before, CON M (before and after), CON F 
(before and after), and ISO M before; $ p<0.05 vs. gender-matched CON group. 
 
 
 
Figure 14: Effects of gender, 5 days of isoproterenol or saline administration and 
acute administration of isoproterenol or saline on left ventricular diastolic relative 
wall thickness in male and female rats. 
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3.2.5 Left ventricular end systolic diameter 
Similar to left ventricular end diastolic diameters, two-way repeated measures 
ANOVA of left ventricular systolic diameters revealed a regimen effect (p<0.0001), a gender 
effect (p<0.001), a time effect (p<0.0001) and a time-regimen interaction (p<0.0001). At 
baseline significant gender differences were noted, with the male rats having greater 
(p<0.0001) left ventricular end systolic diameters compared to the female rats (Figure 15). 
Five days of isoproterenol administration had no effect on left ventricular end systolic 
diameters in either male or female rats; however, consistent with a positive inotropic effect, 
acute isoproterenol administration decreased the left ventricular end systolic diameters in 
both male and female rats (Figure 15).  
3.3 ELISA estrogen levels 
The mean estrogen concentration in the female rats was greater than the mean estrogen 
concentration measured throughout the estrus cycle in rats (Yang et al 2004) (Figure 16). 
Hence, the rats were indeed terminated during proestrus (peak estrogen concentrations).  As 
expected female rats had higher (p<0.01) estrogen concentrations compared to the males rats 
(Figure 16). Importantly, 5 days of isoproterenol administration had no effect on plasma 
estrogen concentrations (ISO F: 23.00±3.47; CON F: 19.31±3.66; ISO M: 7.04±1.41; CON 
M: 7.14±0.53pg.ml
-1
).  
3.4 Cardiomyocyte apoptosis 
On two-way ANOVA of cardiomyocyte apoptosis data, a regimen effect (p=0.0002) 
and a regimen-gender interaction (p=0.013) were noted. The latter is important as it 
demonstrates that the isoproterenol induced cardiomyocyte apoptosis was gender specific. 
Indeed, on post hoc analysis, five days of isoproterenol administration induced 
cardiomyocyte apoptosis in the male rats, an effect which was not evident in the female rats 
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B=before (baseline) an injection of saline (CON F and CON M, hatched bars) or 
isoproterenol (ISO F and ISO M, hatched bars); A=after an injection of saline (CON F and 
CON M, cross-hatched bars) or isoproterenol (ISO F and ISO M, cross-hatched bars); # 
p<0.001 vs. males; * p<0.0001, ISO M after isoproterenol injection vs. ISO M before, CON 
M (before and after), CON F (before and after), and ISO F before; † p<0.0001, ISO F after 
isoproterenol injection vs. ISO F before, CON M (before and after), CON F (before and 
after), and ISO M before. 
 
 
 
Figure 15: Effects of gender, 5 days of isoproterenol or saline administration and acute 
administration of isoproterenol or saline on left ventricular end systolic diameter in 
male and female rats. 
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* p< 0.01 vs. male rats; mean values throughout the estrus cycle as measured by Yang et al 
(2004) are shown for comparison.   
Figure 16:  Plasma estrogen concentrations in female rats and in male rats. 
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(ISO M vs, ISO F, p=0.039) (Figure 17). In addition, the percentage cardiomyocyte apoptosis 
was increased in the male rats receiving isoproterenol in comparison to both the male rats 
receiving saline (p=0.0002) and the female rats receiving saline (p=0.0018) (Figure 17). 
3.5 Cardiomyocyte necrosis and fibrosis 
Non-parametric ANOVA revealed a p value of 0.0028 between groups. On post hoc 
analysis (Kruskal-Wallis test) five days of isoproterenol administration significantly 
increased (p=0.015) necrosis and fibrosis in male rats, an effect not observed in the female 
rats (Figure 16). Five days of saline administration had no effect on cardiomyocyte necrosis 
and fibrosis in either the male or the female rats (Figure 18).  
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* p<0.05 vs. CON M; CON F and ISO F. 
  
Figure 17: Effects of five days of isoproterenol or saline administration on percentage 
cardiomyocyte apoptosis in male and female rats. 
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* p<0.01 vs. CON M; ISO F and CON F. 
 
 
Figure 18:  Effects of five days of isoproterenol or saline administration on pathological score 
(necrosis) in male and female rats. 
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Chapter 4 
Discussion 
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4 Discussion 
4.1 Introduction 
The main findings of my study were that 5 days of β-adrenergic receptor activation, at a 
dose which produced positive inotropic and chronotropic effects, induced cardiomyocyte 
apoptosis and increased myocardial pathological score in male rats but not in female rats. The 
gender differences in cardiomyocyte apoptosis and pathological score were not accompanied 
by differences in cardiac responses to β-adrenergic activation. Heart rates however were 
lower in the female compared to the male rats, an effect which was noted in both the female 
rats receiving 5 days of saline as well as the female rats receiving the β-adrenergic agonist for 
5 days. Five days of β-adrenergic agonist administration resulted in modest cardiac 
hypertrophy in both male and female rats, after the correction for differences in body weight. 
Compared to male rats, female rats had concentric hypertrophy as demonstrated by increased 
diastolic relative wall thickness (RWT) and decreased chamber area. Importantly the data 
were collected when the female rats were in proestrus, thus ensuring that the data was 
collected in the female rats when they were at their peak estrogen concentration.  
4.2 Uniqueness of current study  
This is the first study in vivo where the heart of male rats has been compared to that of 
female rats, in the absence of any manipulation of the sex steroids. Previous in vivo studies 
have assessed the impact of ovariectomy in the presence or absence of exogenous estrogen 
administration. Importantly in these studies the exogenous estrogen was administered at 
supraphysiological doses and hence these studies fail to address the possible impact of 
endogenous concentrations of estrogen. In this regard van Eickels et al (2003) reported that 
exogenous estrogen administration to ovariectomised female mice resulted in a reduction in 
LAD coronary artery induced infarct size and cardiomyocyte apoptosis. Importantly the 
concentrations of estrogen in ovariectomised mice after replacement with exogenous estrogen 
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was 81pg.ml
-1
 (van Eickels et al 2003) as compared to the peak estrogen concentrations of 
23pg.ml
-1 
reported in the current study (female rats terminated during proestrus, peak 
estrogen concentrations)  as well as 8 pg.ml
-1
on average as demonstrated by Jang et al (2004). 
Hence, although excessively high concentrations of estrogen have been reported to be 
cardioprotective; the current study is the first to demonstrate the cardioprotective effects of 
endogenous estrogen concentrations in vivo. Our data showing lower heart rates in female 
rats compared to male rats, as well as enhanced β-adrenergic receptor induced cardiomyocyte 
apoptosis and pathological score in male rats but not female rats, suggest that even 
endogenous concentrations of oestrogen are cardioprotective; however the possible role of 
the hormone progesterone cannot be ignored.  In this regard a study of the effects of gender 
on aging induced cardiomyocyte apoptosis in normal human hearts, demonstrated that 
cardiomyocyte apoptosis was three fold greater in males compared to females (Mallat et al 
2001). Furthermore, Mendelsohn and Karas (2005) showed that myocardial contractility is 
increased in healthy women as compared to age-matched healthy men.  
In addition, this is the first study, to our knowledge, to show in vivo a gender 
discrepancy in β-adrenergic receptor induced cardiomyocyte apoptosis. These data 
corroborate the findings of Gao et al (2003), in that male transgenic mice with β-adrenergic 
receptor overexpression had lower survival rates compared to female transgenic mice. 
Although it has previously been shown that β-adrenergic receptor activation induces 
cardiomyocyte apoptosis, an effect which is ameliorated by β-adrenergic blockade, these 
studies were collected in cultured cardiomyocytes (Communal et al 1998 and Saito et al 
2000) and the impact of gender was not assessed.  
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4.3 Benefits of in vivo compared to ex vivo studies  
This is the first study to our knowledge, to evaluate gender differences in an in vivo 
animal model. The advantage of an in vivo model is that the effects of β-adrenergic receptor 
stimulation are determined throughout the whole physiological system and not in an isolated 
environment. In this regard, Kim et al (2006) demonstrated that exogenous estrogen 
attenuated hypoxic re-oxygenation induced cardiomyocyte apoptosis and reactive oxygen 
species production in cultured cardiomyocytes. The latter study was a short term study 
whereby hypoxic re-oxygenation lasted 18 hours and the TUNEL technique was used to 
assess cardiomyocyte apoptosis; two attributes which are similar to the present study. 
However, there are certain limitations namely; Kim et al (2006) used neonatal cultured 
cardiomyocytes which are immature in nature, and cell culture studies fail to assess the 
effects of other normal physiological systems that impact on the myocardium. To elaborate, 
cultured cells represent an isolated environment which therefore lacks the influence of the 
neurohormonal system to maintain normal physiological homeostasis.  
4.4 Comparisons with previous studies 
4.4.1 Degree of apoptosis  
In the short term study performed by Kim et al 2006 the concentration of 
cardiomyocyte apoptosis as detected by TUNEL was extremely high, 3% TUNEL positive 
cells in cultured cells (Kim et al 2006), as compared with the present study in which 5 days 
ISO administration only induced 0.06% apoptosis. The significantly greater percentages of 
apoptosis observed in vitro compared to in vivo were confirmed by a study which assessed 
the effects of exogenous  estrogen administration on cardiomyocyte apoptosis in both in vivo 
and in vitro animal models (Patten et al 2004). Myocardial infarctions were induced by LAD 
coronary artery ligation in vivo and cardiomyocyte apoptosis was evaluated after 6, 24 and 72 
hours (short term study). LAD coronary artery ligation increased the amount of 
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cardiomyocyte apoptosis with TUNEL values of 2%, 1.3% and 0.8% corresponding to 6, 24 
and 72 hours in placebo treated mice. However, in mice treated with exogenous estrogen, 
LAD coronary artery ligation induced cardiomyocyte apoptosis was attenuated at 24 and 72 
hours with TUNEL values of 0.5% and 0.3% respectively. Moreover, in the in vitro model 
(cultured cardiomyocytes, apoptosis induced by antracycline and daunorubicin)  the 
percentage cardiomyocyte apoptosis determined using TUNEL was 31.5% within 24 hours, 
an effect which was attenuated with exogenous estrogen administration (TUNEL value of 
26.1%) (Patten et al 2004). Importantly, in the in vivo model the highest percentage of 
cardiomyocyte apoptosis was 2% as compared to 31.5% in cultured cardiomyocytes; hence 
confirming that the percentage cardiomyocyte apoptosis is far greater in in vitro models.  
It may be argued that although gender differences were observed in the current study, 
the percentage apoptosis was small. Isolated cardiomyocytes exposed to ISO for an acute 
period of 48 hours produced a 40% increase in apoptosis (Iwai-Kanai et al 1999). However, 
in the present in vivo study a maximum 0.1% increase in apoptosis was observed after five 
days of ISO administration. Importantly, in vitro cultured cardiomyocytes are exposed to an 
isolated environment with no external influences and could therefore produce an exaggerated 
response to β-adrenergic receptor stimulation. An in vivo model, on the other hand, such as in 
the present study, presents a realistic physiological outcome. Furthermore, Colucci (1997) 
explained that a 0.2% increase in cardiomyocyte apoptosis per day, if sustained for a year, 
could result in half the functioning cardiomyocytes being destroyed and consequently induce 
severe myocardial damage. Therefore, a 40% increase in apoptosis after 48 hours does not 
represent a realistic clinical picture; whereas the present study demonstrates a more realistic 
increase in cardiomyocyte apoptosis (0.1% after 5 days) which if sustained for a longer time 
period could induce severe myocardial remodelling. Indeed, Veliotes et al (2005) revealed 
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that long term exposure to ISO (five months) induced changes in left ventricular geometry, 
cardiac dilatation and pump dysfunction.  
4.4.2 Degree of necrosis 
In conjunction with the gender differences in ISO induced apoptosis, the current study 
also revealed a gender difference in pathological scores, which are an index of necrosis and 
replacement fibrosis. Short term administration of ISO significantly increased the 
pathological score in male rats, an effect not demonstrated in the female rats. In accordance 
with the present study’s results that estrogen possibly prevents ISO-induced necrosis, Booth 
et al 2001 demonstrated that 17β-estradiol administration decreased LAD coronary artery 
ligation induced necrosis in ovarectomised female rabbits. However, unlike in the present 
study, no gender comparisons were made. Hence, the study of Booth et al (2001) only 
revealed that exogenous estrogen administration inhibits LAD coronary artery ligation 
induced necrosis. Similarly, Jeanes et al (2008) revealed that ovariectomized female rats 
receiving exogenous 17β-estradiol were protected against ischaemic-reperfusion induced 
myocardial damage by significantly decreasing myocardial necrosis again highlighting the 
importance of estrogen and its plausible cardioprotective effects. It is important to note 
however, that the current study is the first study to our knowledge to evaluate the impact of 
gender on β-adrenergic receptor induced necrosis and replacement fibrosis.  
4.4.3 Degree of hypertrophy 
Before the correction for differences in body weight, the present results revealed 
hypertrophy in ISO treated male rats and not in the ISO treated female rats. However, after 
both heart weight and left ventricular weight had been corrected for 100g body weight, a 
modest increase in heart and left ventricular weight (hypertrophy) was noted in both genders 
in response to 5 days of ISO administration. The female rats were noted to have a greater 
degree of concentric hypertrophy compared to male rats as demonstrated by an increased 
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relative wall thickness and chamber dimensions. However, as with heart and left ventricular 
weights per 100g body weight, no gender differences in the response to ISO were noted. 
Previous research has revealed that females present with a greater degree of concentric 
hypertrophy in response to pressure overload and hypertension induced MI as compared to 
males (Douglas et al 1998; Jain et al 2002). Moreover, human studies have demonstrated that 
postmenopausal women respond to aortic stenosis and systolic hypertension by concentric 
hypertrophic remodelling as opposed to men who present with eccentric cardiac hypertrophy 
(Aurigemma et al 1995). In accordance with the latter statement and the current study, 
Podesser et al (2006) revealed that in a pressure overload model, female rats responded by 
developing concentric hypertrophy as compared to males who developed eccentric 
remodelling.  
 It is possible that 5 days ISO administration was too short a time to detect a gender 
difference in the response to ISO. Indeed, Skavdahl et al (2004) revealed that hypertrophy 
was more pronounced in male mice as compared to age matched female mice after TAC 
induced pressure overload. However, the animal model used by Skavdahl et al (2004) was 
different from the present study. Indeed, TAC induced pressure overload is an extremely 
aggressive model of myocardial insult and thus could have resulted in a gender difference in 
cardiac hypertrophy over a short period of time (2 weeks). It has also been noted that during 
the aging process myocardial mass is maintained better in women compared to men 
(Mendelsohn and Karas, 2005). In accordance with the latter statement in the study 
performed by van Eickels et al (2001) pressure-overload induced myocardial hypertrophy 
was significantly reduced in ovariectomised female mice receiving exogenous estrogen as 
compared to placebo treated ovariectomised mice. Although the study of van Eickels et al 
(2001) was not a gender study it does emphasize the cardioprotective effects of estrogen and 
the role that estrogen plays in decreasing myocardial hypertrophy.   
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4.4.4 Gender differences in heart rate 
       An interesting finding of our study was that male rats had higher heart rates compared to 
female rats at baseline measurements. It is well established that heart rate and contractility are 
controlled by the SNS, more specifically β-adrenergic receptors (Dorn 2002). The latter point 
was demonstrated by Thawornkaiwong et al (2003) whereby estrogen and progesterone 
decreased the expression of β-adrenergic receptors in ovariectomized female mice. In 
addition it was also noted that long term ovarian hormone deprivation produced significant 
up-regulation of β-adrenergic receptors. The latter study could offer a plausible explanation 
as to why female rats had lower baseline heart rates in the current study. It is possible that 
estrogen down-regulated myocardial β-adrenergic receptor activity and thus induced lower 
heart rates in female rats as compared to male rats. Indeed, in a study in which rat hearts and 
ventricular myocytes were treated with estrogen and ISO, estrogen administration was found 
to prevent the ISO-induced increase in heart rates, diastolic pressure and ischemic induced 
arrhythmias (Li et al 2000).  An important note regarding the study of Li et al (2000) is that 
the dose of estrogen used was in the normal physiological range of estrogen concentrations, 
which coincides with the present study in which female rats were examined during normal 
estrus cycle and presented with lower heart rates as compared to males.  Interestingly, Skafar 
et al (1997) showed that estrogen has a direct effect on vascular smooth muscle cell (VSMC) 
function, more specifically contractility and growth. Research reveals that estrogen decreases 
voltage-dependent T and L-type calcium channel currents within the VSMC and thus 
hyperpolarizes the resting membrane potential which consequently attenuates myocardial and 
vascular contractility (Skafar et al 1997). In addition, estrogen has also been shown to 
attenuate angiotensin II and noradrenaline induced contractility, two mediators which induce 
the release of calcium from intracellular storage sites and hence increase contractility (Skafar 
et al 1997). Hence, it is likely that the lower heart rates measured in the female compared to 
the male rats, are due to the high estrogen concentrations in the females during proestrus. 
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Nevertheless, the increment in heart rate observed in response to acute isoproterenol in the 
female rats was greater than that observed in the male rats. An explanation for the increased 
acute response in the females despite possible down regulation of β-adrenergic receptors in 
response to 5 days of ISO administration is unclear.   
4.5 Different models of CVS disease 
The β-adrenergic receptor activation model is of significant clinical value as heart 
failure is accompanied by over-activation of the sympathetic nervous system and increased 
plasma concentrations of noradrenaline (Tan et al 2004). In comparison, previous in vivo 
models which have demonstrated gender differences do not closely resemble the slow 
progression of heart failure. In this regard both TAC and LAD are aggressive models of acute 
pressure-overload, and acute hypoxia and MI respectively. Hence these data are difficult to 
translate into possible clinical impacts.  To elaborate van Eickels et al (2001) induced 
pressure overload hypertrophy by TAC within a period of 4-8 weeks. Generally, hypertrophy, 
cardiac remodelling and heart failure are slow processes, thus the short term effects of TAC 
(i.e. 4-8 weeks) fail to mimic the natural progression of cardiac dysfunction. Moreover, the 
effects of acute MI may differ from the mechanisms responsible for chronic heart failure. 
Conversely, Veliotes et al (2005) demonstrated that low dose ISO for a period of 4.5 months 
induced pump dysfunction and increased left ventricular cavity volume; physiological 
changes that normally occur in chronic heart failure. Thus, although TAC and LAD have the 
potential to induce myocardial damage the mechanisms are aggressive and do not correlate 
with the natural progression of chronic heart failure unlike the usage of ISO which favours 
the natural progression of cardiovascular disease in both short term and long term use 
(Osadchii et al 2007 and Veliotes et al 2005). Another CVS model of disease is the over-
expression of β-adrenergic receptors. Gao et al (2003) revealed that male transgenic mice 
with β2-adrenergic receptor over-expression had lower survival rates as compared to female 
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transgenic mice, thus highlighting the possible cardioprotective effects of estrogen via β2-
adrenergic receptors. Although β2-adrenergic receptor over-expression induced left 
ventricular dilatation and reduced left ventricular fractional shortening, the shortcoming of 
this model is that the animals are genetically manipulated and hence do not truly represent the 
natural progression of heart failure in humans.   
4.6 Different manipulations of estrogen concentrations 
           In the present study estrogen concentrations were not manipulated as female animals 
were used to assess the effects of the natural estrus cycle. However, in the literature various 
models of estrogen manipulation have been assessed. One such example of estrogen 
manipulation is estrogen receptor knockout models (Pelzer et al 2005; Korte et al 2005). 
Indeed, Pelzer et al (2005) demonstrated that female estrogen β-receptor knockout mice had 
increased mortality rates, infarct sizes and biochemical markers of heart failure as compared 
to wild type mice receiving exogenous 17β-estradiol. The study revealed the cardioprotective 
effects of estrogen more specifically the role of the ER-β. Although receptor knockout 
models are useful in detecting the possible function of a receptor, they fail to assess normal 
physiological mechanisms as well as the effect of other receptors involved such as the other 
estrogen receptor, ER-α.  In another study, Skavdahl et al (2004) analysed the effect of TAC 
in female ER-α and ER-β knockout mice. The results demonstrated that the ER-β knockout 
mice had a greater degree of hypertrophy compared to wild type female mice and this effect 
was not noted in the ER-α knockout female mice; thus revealing that estrogen is 
cardioprotective and could possibly protect the myocardium via ER-β. 
      The current study is the first study, to our knowledge, which assesses the effects of ISO 
induced cardiomyocyte apoptosis and necrosis in normal cycling female rats. Various studies 
have assessed the effects of estrogen; however these studies have manipulated estrogen and 
not identified the mechanisms of the endogenous estrus cycle. Indeed, van Eickels et al 
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(2003) assessed the effects of estrogen in LAD coronary artery ligation induced 
cardiomyocyte apoptosis in female mice. The results were favourable in that estrogen 
attenuated LAD coronary artery ligation induced apoptosis; however the mice were 
ovarectomised and received constant high levels of exogenous 17β-estradiol at concentrations 
of 81 pg.ml
-1
. Conversely, in the present study female rats had decreased cardiomyocyte 
apoptosis and necrosis as compared to male rats and revealed peak estrogen concentrations of 
23  pg.ml
-1
. Moreover, Zhan et al (2008) investigated the effects of low, medium and high 
doses of exogenous estrogen in female mice post-MI (LAD coronary artery ligation). The aim 
of the study was to address the controversy regarding the correct and most physiological dose 
of estrogen that should be administered in animal models. The results demonstrated that low 
dose exogenous estrogen tended to be more cardioprotective, that is improved myocardial 
function and remodelling, as compared to medium and high doses of estrogen (Zhan et al 
2008). In addition, moderate and high doses of estrogen increased myocardial fibrosis, 
hypertrophy, dysfunction and dilatation. The importance of the study of Zhan et al (2008) is 
that it emphasises that low doses but not medium or high doses of estrogen are 
cardioprotective. Hence the study of Zhan et al (2008) corroborates the present study, which 
shows that normal physiological concentrations of estrogen are cardioprotective and crucial 
for myocardial homeostasis.  
It is well understood that human studies are controversial regarding HRT. One theory 
that has been explored is whether the dose of HRT is too high. Indeed, Varas-Lorenzo et al 
(2000) assessed the effects of high, medium and low dose HRT in healthy post menopausal 
women and the effective incidence of MI. The results demonstrated that medium doses 
produced the most favourable odds ratio as compared to high and low dose HRT. Thus, this 
study agrees with the results of Zhan et al (2008) that the dose of estrogen is crucial when 
assessing the cardioprotective mechanisms of estrogen.        
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4.7 Possible mechanisms of protective effects of estrogen 
         The present study reveals that a marked gender difference exists with female rats having 
less cardiomyocyte apoptosis and necrosis in response to ISO as compared to age matched 
male rats. It can be postulated that a relationship exists between estrogen receptors and the β-
adrenergic receptors of the SNS. Indeed, Kam et al (2004) demonstrated that long term 
estrogen administration suppresses myocardial β1-adrenoceptors in ovariectomized female 
rats which consequently decreases myocardial injury during ischaemic induced SNS hyper 
stimulation (Kam et al 2004). In the study of Kam et al (2004), ischemia was produced by 
LAD coronary artery ligation and female rats were either intact; ovariectomized receiving 
exogenous 17β-estradiol; or ovariectomized receiving placebo. In order to mimic SNS hyper-
stimulation, ISO was administered during the ischemic period (LAD coronary artery ligation) 
and revealed that infarct sizes increased significantly in ovariectomized rats receiving 
placebo as compared to intact rats and ovariectomized rats receiving 17β-estradiol. In order to 
assess the effects of estrogen on β-adrenergic expression, Kam et al (2004) measured the 
mRNA expression and protein concentration of β-adrenergic receptor in the left ventricular 
tissue of the different groups. Interestingly, β-adrenergic receptor levels were up-regulated in 
ovariectomized rats and suppressed in intact and ovariectomized rats receiving exogenous 
17β-estradiol, thus highlighting the possible cardioprotective mechanism of estrogen is by 
down regulation of β-adrenergic receptors. In a follow up study, Kam et al (2005) further 
investigated the relationship between estrogen and β-adrenergic receptors. Indeed in the latter 
study, Kam et al (2005) revealed that estrogen inhibits protein kinase A (PKA) activity which 
decreases calcium influx via calcium channels and consequently decreases myocardial 
contractility. The interactive effects of estrogen on β-adrenergic receptors support the results 
of the present study that natural estrogen attenuated ISO induced apoptosis and necrosis in 
female rats, but not in male rats.  
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         In order to investigate the possible cardioprotective mechanisms of estrogen, Kim et al 
(2006) assessed the role that estrogen plays in preventing hypoxic re-oxygenation induced 
cardiomyocyte apoptosis. Cultured rat cardiomyocytes were treated with estrogen or placebo 
and chemicals that induced hypoxic re-oxygenation. The results demonstrated that estrogen 
treated cells had less cardiomyocyte apoptosis as assessed by annexin V staining and the 
TUNEL technique. In addition, the exact apoptotic pathway was assessed and revealed that 
estrogen blocked the activity of p38α kinase, a protein involved in pro-apoptotic pathways. 
The production of reactive oxygen species (ROS), was also measured and demonstrated that 
estrogen attenuated hypoxic re-oxygenation induced ROS which is a potent mediator of cell 
death. In agreement with Kim et al (2006), Patten et al (2004) also assessed plausible 
mechanisms for decreased apoptosis in cardiomyocytes treated with estrogen and revealed 
that estrogen increased the stimulation of the pro-survival pathway, serine-threonine, Akt and 
PI3 kinase dependent pathway. Thus both studies highlighted that estrogen prevents pro-
apoptotic pathways as a plausible mechanism of cardioprotection.              
4.8 Possible mechanisms for gender differences 
      Females have improved myocardial function and survival rates in both human and animal 
studies (Mendelsohn and Karas 2005; Guerra et al 1999; Zhai et al 2000; Skavdahl et al 2004; 
van Eickels et al 2001). A plausible reason for these gender differences, are gender 
differences in the cardiac expression of glycolytic and mitochondrial metabolic enzymes as 
well as the pro-survival effects of ER2-ER on cardiomyocytes which is controlled by ER-α 
and phosphatidylinositol 3-kinase-Akt-dependent pathways (Mendelsohn and Karas, 2005). 
Indeed, Guerra et al (1999) demonstrated that failing hearts in human females had less 
cardiomyocyte death as compared to those in human males. The authors postulated that 
estrogen improved the phosphorylation of insulin growth factor-1 (IGF-1) which increases 
the expression of anti-apoptotic gene products such as  Bcl-2 and Bcl-x1 and inhibits Bax, a 
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pro-apoptotic protein; thus decreasing the degree of apoptosis in females. Cavasin et al 
(2003) revealed that female mice post MI had less myocardial dysfunction and chronic 
remodelling as compared to male mice post MI. Moreover, in the latter study, non-castrated 
male mice receiving exogenous estrogen had improved myocardial function and decreased 
remodelling. The authors explained that estrogen was shown to increase nitric oxide 
production which induces rapid dilation of coronary arteries (Williams et al 1992) and 
furthermore, estrogen increases HDL concentrations, improves endothelial function and 
prevents inflammatory cell activation (Pelzer et al 1996), all of which could explain the 
cardioprotective effects of estrogen.  
        Indeed, Jovanovic et al (2000) assessed whether a gender difference exists in the 
response to metabolic stress. Single ventricular cardiomyocytes were used and underwent 
hypoxic re-oxygenation. Cardiomyocytes from either gender had increased calcium loading, a 
predictor of cellular damage, in response to hypoxic re-oxygenation. However, when 
pretreated with 17β-estradiol female cardiomyocytes had less hypoxic re-oxygenation 
induced calcium loading an effect not demonstrated in the male cardiomyocytes. Moreover, 
administration of tamoxifen, an estrogen receptor blocker, prevented the estrogen induced 
decrease in calcium loading thus demonstrating that the decrease in calcium was estrogen 
dependent. The authors explained that the gender difference could be as a result of estrogen 
receptors being more functional and present in higher concentrations in females as compared 
to in males (Jovanovic et al 2000).        
      
4.9 Limitations 
The present study has certain limitations which must be addressed. The study 
demonstrated ISO induced cardiomyocyte apoptosis, necrosis and replacement fibrosis in 
male rats, but not in the female rats. However, whether the effect was in fact as a result of the 
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presence of testosterone, rather than the absence of estrogen, in male rats was not elucidated. 
Hence further research must assess the effects of testosterone on ISO induced cardiomyocyte 
apoptosis and pathological score. Moreover, the effects of progesterone in the female rats 
were not assessed or measured. However in the present study we chose to focus on the effects 
of estrogen, rather than progesterone, as evidence from the literature points towards estrogen 
being the most likely cardioprotective female hormone. In addition certain limitations exist 
with the techniques used. TUNEL was used to quantify the percentage of cardiomyocyte 
apoptotic nuclei. Although it is a widely used technique for the detection of fragmented 
DNA, a biochemical feature of apoptosis, TUNEL is extremely sensitive and stains 
fragmented DNA of cells undergoing repair. Thus, over estimation of the total number of 
apoptotic nuclei could have occurred (Jugdutt and Idikio 2005). Moreover, the precise stage 
of apoptosis, early or late, could not be determined and necrotic cells were not easily 
distinguished from apoptotic cells. Alternative methods for evaluating apoptosis and the 
distinguished stages are caspase-3 activity and flow cytometry (Annexin V and propidium 
iodide). However, in order to assess caspase activity, the hearts would need to have been 
freeze clamped hence precluding the assessment of cardiac weights and apoptosis via 
TUNEL. Flow cytometry requires the use of isolated cardiomyocytes, preferably those grown 
in cell culture, as the isolation procedure (collagenase digestion) is likely to result in 
alterations in the cell membrane and thus the signs of early apoptosis (annexin V binding) 
would be masked by overall propidium iodide staining. Nevertheless, the purpose of the 
study was not to quantify accurately the degree and stage of apoptosis; but rather to assess in 
vivo the impact of gender on the degree of ISO induced cardiomyocyte apoptosis and 
necrosis. The estrogen ELISA assay that was used was a human assay, as rodent assays are 
currently not available. However the aim of the assay was to verify that female rats had 
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higher concentrations of estrogen as compared to male rats, rather than to quantify the exact 
concentrations of estrogen.   
       In future studies we plan to investigate ISO induced apoptosis and necrosis in 
ovariectomized compared to naturally cycling female rats to confirm the results observed in 
the present study. Also, to investigate the effects of pharmacologically blocking estrogen and 
assessing the effects in female rats both naturally cycling and ovariectomized receiving 
exogenous estrogen.  Moreover, it is important to determine whether the presence of 
testosterone (rather than the absence of estrogen) is in fact cardiotoxic. In this regard, in 
future studies we plan to evaluate the effect of castration on ISO induced apoptosis and 
necrosis in male rats. It is also important to investigate the effects of long term ISO 
administration in male and female rats and elucidate whether estrogen attenuation of 
cardiomyocyte apoptosis and necrosis translates into protection of the female heart from ISO-
induced cardiac dilatation and chamber dysfunction in vivo. In addition, the effects of the 
different stages of the estrus cycle on β-adrenergic induced apoptosis and necrosis can be 
assessed; however this must be done with caution as certain stages of the estrus cycle are 
extremely short and thus could be missed on examination (The four stages of the rat estrus 
cycle, namely proestrus, estrus, metestrus and diestrus last twelve, twelve, twenty one and 
sixty hours respectively, hence the estrus cycle lasts a total of 4 days and 19 hours 
(Marcondes et al 2002).   
4.10 Clinical implications 
        It is well established that patients in heart failure and myocardial infarction have 
increased levels of noradrenaline (Tan et al 2004). In addition, increased stimulation of the 
SNS and even more specifically β-adrenergic activation is an early indication of myocardial 
damage (Communal et al 1998). Thus, it is crucial to evaluate the possible detrimental effects 
of prolonged β-adrenergic stimulation. In this regard, prolonged β-adrenergic stimulation 
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results in myocardial apoptosis and necrosis, which contribute to myocardial dysfunction and 
dilation, by the loss of viable functioning cardiomyocytes. Thus, investigating the 
mechanisms of the effects of activation of the β-adrenergic system is crucial. Moreover, 
research has established a relationship between β-adrenergic receptors and estrogen 
(Thawornkaiwong et al 2003; Kam et al 2003 and Vizgirda et al 2002), indicating that 
estrogen is cardioprotective. Further knowledge of the relationship between estrogen and β-
adrenergic receptors, and the mechanisms of the protective effects of estrogen against β-
adrenergic induced cardiac dysfunction, is crucial for the development of possible drug 
targets for cardioprotection.    
4.11 Conclusion  
           Thus in conclusion, this is the first study, to our knowledge, that demonstrates a 
gender difference in the cardiac response to short term β-adrenergic stimulation in vivo. The 
present study demonstrates the possible cardioprotective effects of estrogen by decreasing β-
adrenergic induced cardiomyocyte apoptosis and necrosis, although the possible effects of the 
hormone progesterone cannot be ignored. The latter is important as it sheds light on a 
plausible mechanism of how endogenous estrogen is cardioprotective and will allow for 
further research to fully elucidate how estrogen attenuates β-adrenergic induced myocardial 
damage. 
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